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 Live, attenuated vaccinations have been successful in the generation of protective 
immunity to a variety of illnesses, such as the measles, mumps, and rubella, but have had 
limited success as therapeutic cancer treatments. We explored the differences in the 
cellular and molecular immunity generated by a new Listeria Monocytogenes vaccine 
platform, as compared to the well characterized Vaccinia Virus. Listeria-OVA 
vaccination resulted in the slowest tumor growth in subcutaneous models, as well as 
decreased tumor burden and increased survival in a metastatic model. This benefit was 
dependent on the generation of adaptive immunity, as antibody depletion of CD8+ T cells 
significantly impaired the survival benefit of the Listeria-OVA vaccine. To examine the 
effects of these vaccines on the early stages of CD8+ T cell development, we adoptively 
transferred OVA specific CD8+ T cells (OT-1) into host mice prior to vaccination. 
Surprisingly, we found that Listeria-OVA vaccine resulted in CD8+ T cell activation 
without significant expression of PD-1 or LAG-3, unlike the Vaccinia-OVA vaccine or 
any other vaccine currently reported. The activation of CD8+ T cells without PD-1 was 
completely dependent on the genetic deletion of the ActA gene from the Listeria vector, 
as wildtype Listeria-OVA did not replicate this phenotype. Strikingly, despite differences 
in wildtype mice, both vaccines were similarly effective in increasing overall survival in 
PD-1-/- mice, suggesting that the difference in induced PD-1 expression was responsible 
for the difference in efficacy. To better understand this phenotype, we developed a direct 
ex vivo antigen detection assay, and found that both Vaccinia-OVA and Listeria-OVA are 
primarily presented to naïve CD8+ T cells by CD8α+ dendritic cells (CD8α+ DC), and 
that Listeria-OVA vaccinated CD8α+ DCs are sufficient to drive naïve CD8+ T cell 
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division without PD-1 expression in a contact dependent manner. Finally, we performed 
microarray analysis on CD8α+ DCs 24 hours after vaccination, and found a dramatic 
difference in the RNA expression profile of a Listeria-OVA vaccinated CD8α+ DCs. 
Together, these data show that checkpoint protein expression is not uniformly associated 
with CD8+ T cell activation, and that individual cancer vaccine vectors may increased 
clinical benefit due to their modulation of checkpoint protein expression. 
Thesis Readers 
Charles G. Drake, MD, PhD, Thesis Advisor 





  The following work was done in an attempt to further my personal knowledge of 
the field of immunology, as well as to try and advance the understanding of the field as a 
whole. Doing these experiments has helped me to realize that there will always be new 
questions to answer, and that it is as important to enjoy the process of discovering new 
ideas and information as it is to enjoy the final product. 
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In the past two decades, the field of immunology has begun to develop an 
understanding of the complex interactions between the immune system and cancer. From 
the findings that immunocompromised mice1 and humans2,3 have an  increased incidence 
of tumor formation, to the discovery that cancer patients have tumor specific CD4+ and 
CD8+ T cell populations, it has become clear that the immune system plays a prominent 
role in the control of cancer. Yet, by the time of clinical diagnosis, the tumor has been 
edited to avoid immune surveillance, as was shown in an elegant series of animal studies. 
In these experiments, it was found that tumors that had been grown in the absence of an 
adaptive immune system were often rejected or slowed when transferred into an immune-
competent host4. However, when the tumors were grown in an immune-competent host 
first, growth was no longer impeded when they were transferred to a new host. Together, 
these data suggested that the immune system is capable of rejecting cancer, and does 
interact and recognize cancerous cells naturally. Yet, by the time of clinical treatment, the 
tumor has already avoided or tolerized the immune system. Therefore, the goal of cancer 
immunotherapy is to reactivate the immune system, and provide acute and long term 
rejection of cancer in the form of immune memory. Two areas of preclinical research that 
have shown the most progress are the development of cancer vaccinations and the 
blockade of checkpoint proteins with monoclonal antibodies. 
CD8+ T Cell Checkpoint Proteins 
Since the arrangement of the T Cell Receptor (TCR) is random, it is unavoidable 
that some CD8+ T cells will be generated with a TCR that is specific for a peptide that the 
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host naturally expresses. Due to the sterilizing nature of immunity, the generation of an 
immune response to a host protein can result in “horror autotoxicus,” or autoimmunity. 
Such a response can be seen in the case of type I diabetes, where patients have CD8+ T 
cells that have targeted the β−islet cells of their liver, resulting in the lifelong eradication 
of these cells and the subsequent lack of insulin production capabilities. To prevent this, 
in addition to central tolerance and CD4+ regulatory T cells, there are a series of 
extracellular receptors called checkpoint proteins that are imposed on the CD8+ T cells 
when they are activated in an inappropriate context5. These proteins have a role in the 
prevention of autoimmunity, but also have been found to be used by tumors as a 
mechanism of immune escape. Many tumors express the ligands for these checkpoint 
proteins, and tumor infiltrating lymphocytes are often found expressing one or more of 
these negative regulators of the immune system. This makes checkpoint proteins an 
attractive target for the generation of anti-tumor immunity5, though future research will 
need to continue to explore the signaling pathways by which these proteins act. 
Cytotoxic Lymphocyte Antigen-4 
The most well understood of the checkpoint proteins is called Cytotoxic 
Lymphocyte Antigen-4, or CTLA-4. CTLA-4 is a homolog of CD28, and has a 
significant role in the maintenance of self-tolerance in the periphery, as shown by initial 
studies using CTLA-4 knockout mice. These mice have an extreme autoimmune-like 
phenotype, and are moribund within a month of being born. This fatal phenotype is 
marked by immune infiltration as well as inflammation of a variety of organs, including 
the pancreas, heart, liver, and lungs6,7. As a homolog of CD28, it is perhaps unsurprising 
that CTLA-4 binds to CD80 and CD86, the main ligands of CD28. However, while CD28 
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binding to CD80 or CD86 provides a stimulatory signal to the T cell, CTLA-4 binding 
these ligands provides an inhibitory signal. Given that the affinity of CTLA-4 for these 
ligands is significantly higher than that of CD28, CTLA-4 binding is able to outcompete 
its positive stimulatory counterpart8. In terms of signaling, CTLA-4 recruits two 
phosphatases, SHP29 and PP2A10, to inhibit T cell receptor signaling.  SHP2, when 
bound to CTLA4 within the immune synapse, is responsible for dephosphorylating the 
CD3ζ chain, decreasing the TCR signaling potential by blocking the activity of FYN and 
LCK, and decreasing the recruitment of ZAP709. Downstream of the TCR signaling 
complex, PP2A decreases the phosphorylation of AKT11, further dampening the signals 
being generated by TCR engagement, and preventing CD8+ T cell activation.  
Programmed Death-1 
Programmed Death-1, or PD-1, is a 55 kD transmembrane protein, which, like 
CTLA-4, is involved in the prevention of CD8+ T cell activation12,13. However, unlike 
CTLA-4, PD-1 knockout mice have a less extreme phenotype, where older animals may 
develop mild lupus-like autoimmunity14 or dilated cardiomyopathy15, depending on the 
background of the animal. Therefore, if CTLA-4 is an on/off switch, PD-1 is more like a 
rheostat for fine tuning the immune response. PD-1 binds to two, distinct ligands with 
unique expression patterns, named PD-L1 and PD-L2 (also known as B7-H1 and B7-
DC). PD-L1 expression can be induced on most cell types, including both immune 
derived cells as well as epithelial and endothelial cells of peripheral organs. Expression of 
PD-L1 can be increased by stimulation with IFNγ or with type I interferons. In this way, 
PD-L1 plays a role in general protection of host cells from CD8+ T cell targeting. In 
contrast, PD-L2 expression was originally thought to be strictly on professional antigen 
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presenting cells. However, some recent data have suggested that PD-L2 may be 
expressed on certain prostate and neurological cell lines, and can be up regulated in 
response to IFNγ (Nirschl, Martin, unpublished results). Expression of PD-1 on CD8+ T 
cells is tightly regulated, and no PD-1 is found on naïve CD8+ T cells due to high 
promoter methylation16.  PD-1 protein is subsequently up regulated during T cell 
activation; however, in this work we show that PD-1 expression may not be a necessary 
consequence of CD8+ T cell activation, but rather is controlled by the programming of 
the presenting dendritic cell. Further research will be necessary to determine the exact 
nature of the proteins responsible for controlling PD-1 expression on T cells. 
Nevertheless, continuous PD-1 expression has also been found on CD4+ and CD8+ T 
cells facing chronic infections, such as LCMV, or during chronic antigen exposure, such 
as during the progression of cancer. These features make PD-1 a promising therapeutic 
target, as will be discussed below.  
PD-1 signaling is similar to CTLA-417 signaling, though evidence of 
combinatorial effects suggests that these proteins do not have completely overlapping 
functions18,19. PD-1 contains two well documented cytoplasmic motifs, an Immuno-
Tyrosine Inhibitory Motif (ITIM) and an Immuno-Tyrosine Switch Motif (ITSM). 
Interestingly, PD-1 utilizes only the ITSM motif to recruit the phosphatases SHP-1 and 
SHP-2, although only SHP-2 recruitment has been confirmed in vivo20. The recruitment 
of SHP-2 to the immunological synapse by PD-1 results in dephosphorylation of the 




Lymphocyte Activation Gene-3 
A third immune checkpoint protein that regulates CD8+ T cells is Lymphocyte 
Activation Gene-3, or LAG-322. LAG-3 is a CD4 homolog23, and as such, has also been 
found to bind to MHC II24. Due to the restrictive nature of MHC II expression, LAG-3 
has a milder regulatory role than either CTLA-4 or PD-1. This has been confirmed in 
LAG-3 knockout animals, where no overt, autoimmune-like phenotype has been 
reported25. However, in models where autoimmunity is initiated, such as the Non-Obese 
Diabetic (NOD) model, LAG-3 knockout animals have more pronounced CD4+ and 
CD8+ T cell infiltration of the pancreas and significantly accelerated disease, 
demonstrating that LAG-3 does have a role in preventing an immune response to 
inappropriate stimuli26. Further research has also shown that LAG-3 knockout animals 
have increased expansion of T cells in response to SEB activation, in vivo peptide 
stimulation, and to Sendai Virus, suggesting that LAG-3 may also play role in the 
regulation of a developing, appropriate immune response27. Current work in our lab has 
also suggested that LAG-3 expression allows for activated CD4+ T cells to be suppressed 
by CD4+ regulatory T cells (Tregs) (Durham, Nirschl Unpublished Data), which fits in 
the above models as Tregs are important in the maintenance of peripheral tolerance, as 
well as is modulating the scope of the adaptive immune response. Currently, it is known 
that LAG-3 has a cytoplasmic KIEELE domain27, and that this domain is required for 
LAG-3 function. Furthermore, we have recently found that STAT5 and IL-2 are required 
for LAG-3 to regulate an immune response during homeostatic proliferation, and that 
LAG-3 blockade can decrease the threshold for STAT5 phosphorylation in response to 
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peptide stimulation. These data suggest that LAG-3 may be signaling through STAT5 to 
prevent T cell activation.  
T Cell Immunoglobulin Mucin-3 
One final checkpoint protein that has been more recently studied in the context of 
cancer is T cell Immunoglobulin Mucin-3, or TIM-3. TIM-3, like the other checkpoint 
proteins, is an extracellular receptor protein, and contains both immunoglobulin and 
mucin domains. Like LAG-3, TIM-3 knockout mice do not show an overt, auto-immune 
like phenotype28, but are more prone to experimental autoimmune disease induction, such 
as in Non-Obese Diabetic Mice (NOD)28, or the initiation of Experimental Autoimmune 
Encephalitis29 (EAE). One of the major ligands for TIM-3 is a secreted lectin named 
Galectin-9. Galectin-9 administration in vitro has been shown to cause death of Th1 CD4+ 
T cells in a TIM-3 dependent manner30. In models of EAE, the disease phenotype was 
significantly reduced by the administration of Galectin-9, which was found to result in 
the deletion of the disease causing, IFNγ expressing CD4+ T cells29, correlating with the 
in vitro data. Like LAG-3 signaling, only a few parts of the TIM-3 signaling pathway in 
T cells are known. Current data suggests that the protein Bat3 acts as an off switch for 
TIM3 signaling, and continuously protects the T cell from the inhibitory signaling 
pathway when no TIM-3 ligands are present31. However, when TIM-3 binds Galectin-9, 
or one of its other ligands, Y265 is phosphorylated on the cytoplasmic end of TIM-3 by 
inducible T cell kinase (ITK)32, displacing Bat3 and allowing TIM-3 signaling to 




Combinatorial Checkpoint Expression  
Taken alone, each of these checkpoint proteins has a clear role in the management 
of the immune system. Furthermore, the controlled expression of the ligands of these 
checkpoint proteins on dendritic cells suggests that one major point of immune regulation 
is during the dendritic cell:T cell priming interaction. However, the complexity of these 
models has increased in recent years, as it has become clear that in many cases, 
combinations of checkpoint proteins are being expressed, especially in the case of 
chronic infections and cancer. In a seminal study using LCMV, Wherry et. al. showed 
that exhausted CD8+ T cells co-express multiple checkpoint proteins, including PD-1, 
LAG-3, 2B4, and CD16033. Co-expression of multiple checkpoint proteins correlated 
with decreased effector cytokine production and lytic function. Other research has also 
suggested that PD-1 and TIM-3 are also co-expressed during chronic LCMV infection, 
and that co-expression of these two checkpoints also correlates with decreased CD8+ T 
cell function34.  
In cancer, the expression of multiple checkpoints on tumor infiltrating 
lymphocytes has made combinatorial checkpoint blockade an attractive target for cancer 
treatment. Indeed, studies publishing the benefits of single checkpoint blockade by 
blocking either the CTLA-435 or PD-l36–38 signaling pathways in clinical settings have 
been documented in the past decade, leading ultimately to CTLA-4 blockade being the 
first FDA approved checkpoint therapy. Preclinically, the first combinatorial blockade 
studies were done combining PD-1 and CTLA-439,40. In these studies, while individual 
blockade showed some anti-tumor immune responses, combinatorial blockade was far 
superior. In mechanistic studies, combining PD-1 and CTLA-4 blockade with an 
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irradiated tumor vaccine resulted in increases of both the CD8+ and CD4+ effector 
populations when compared to regulatory T cells41. While these studies were initially 
done in models of melanoma, the anti-tumor treatment effects of combined PD-1 and 
CTLA-4 blockade have been repeated in models of bladder cancer18, as well as ovarian 
cancer42, demonstrating that combinatorial blockade of PD-1 and CTLA-4 may have 
potential across a broad range of tumor types. 
TIM-3 expression on tumor infiltrating lymphocytes has been confirmed in 
several preclinical tumor models as well, including CT26 colon carcinoma, 4T1 
mammary carcinoma, and B16 melanoma43. Interestingly, TIM-3 was found almost 
universally co-expressed with PD-1, and combined PD-1 and TIM-3 blockade proved to 
be the most effective immunotherapy in terms of anti-tumor immunity. Furthermore, 
mechanistically, expression of multiple checkpoints, in this case TIM-3 and PD-1, was 
found to correlate with decreased expression of effector cytokines, such as IFNγ, IL-2, 
and TNFα, as was seen previously in the viral models of chronic infection. 
Co-expression of PD-1 and LAG-3 represents an important mechanism of self-
tolerance, as these two checkpoints are co-expressed during the recognition of self-
antigen44. These findings were extended through the generation of mice that express 
neither PD-1 nor LAG-3 (DKO mice). In these animals, the normally subtle autoimmune 
phenotypes of the single knockouts is replaced with extreme immune infiltration of the 
heart, lungs, and liver45,46. Additionally, most of these animals are moribund within 6-8 
weeks after birth. Important for cancer therapy, we found PD-1 and LAG-3 were co-
expressed on CD4+ and CD8+ tumor infiltrating lymphocytes in B16 melanoma, SA1N 
fibrosarcoma, and MC38 colon carcinoma. Using SA1N and MC38, we found that 
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tumors implanted on DKO mice were mostly rejected, while tumor growth was only 
delayed in PD-1 single knockout mice and left relatively unaffected by the absence of 
LAG-3. In a more clinically relevant model, we treated established SA1N and MC38 
tumors with monoclonal antibodies against PD-1, LAG-3, or both. Similar to the 
knockout experiments, PD-1 or LAG-3 monotherapy did delay tumor growth, but 
combinatorial blockade resulted in rejection of the majority of the established tumors. 
Furthermore, and perhaps most importantly, combinatorial blockade of PD-1 and LAG-3 
as a treatment model did not induce the extreme auto-immune like infiltration seen in the 
knockout animals45. 
In the clinic, there is mounting evidence of combinatorial expression of 
checkpoint proteins. Cancer testis antigen NY-ESO-1 specific T cells co-express PD-1 
and LAG-3 in ovarian cancer patients47, while the TILs of melanoma patients often co-
express PD-1 and Tim-3atients48. Early clinical studies utilizing CTLA-4 blockade, or 
Ipilimumab, were initially very exciting, as approximately 15% of melanoma patients 
showed objective responses35. Moreover, those patients that did respond showed 
surprisingly long lasting tumor control, which has become a hallmark of successful 
immunotherapy. Likewise, anti-PD-1 therapy, or Nivolumab, has shown responses in 
about 30% of melanoma patients, and those responses are often durable for years36. 
Recent results combining these two blockades have demonstrated similar combinatorial 
effects as seen in preclinical models. Strikingly, patients who responded to combinatorial 
therapy (about 53%) had 80% decreases in tumor size by the first scheduled assessment, 
showing a rapid anti-tumor response49. Only time will tell if these responses will 
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continue, but data from the CTLA-4 and PD-1 individual blockade trials suggest that 
many of these responses will be long lived.  
Cancer Vaccines 
While checkpoint blockade represents the reactivation of a previously generated 
response, in certain pathologies, such as breast, prostate, and kidney, the percentage of 
tumor specific T cells found in patients is relatively low. However, in other cancer types, 
such as melanoma, the frequency of tumor specific T cells is fairly sizable. Currently, it is 
unknown why only some cancers develop significant CD8+ T cell populations, but the 
presence of a significant population of tumor specific T cells is important for the 
generation of anti-tumor immunity50,51. Additionally, without tumor specific T cells, the 
efficacy of checkpoint blockade would be significantly hindered. Luckily, there is already 
a well-established tool for the generation of an adaptive immune response in the clinic, 
known as a vaccination. However, while current protective clinical vaccines are highly 
effective, they do not have to subvert tumor- induced tolerance, and are given 
prophylactically to patients with fully intact and competent immune systems. Anti-cancer 
vaccines must be developed to break tumor induced tolerance, and must show clinical 
benefit in a therapeutic setting. Broadly, cancer vaccines can be divided into three 
categories; DNA Vaccinations, Cell Based Vaccinations, and Live-Attenuated 
Vaccinations. Each of these classes of vaccine has their own strengths and weaknesses, as 






As their name suggests, DNA Vaccines are based on the introduction of naked 
genetic material into the host, with the goal of having this gene or genes expressed to 
generate a potent immune response52–54. One of the primary practical advantages of DNA 
based vaccinations is their potential for easy, large scale generation. Furthermore, DNA 
is extremely stable, and thus could be easily stored and transported with little need for 
technical support. One of major clinical and scientific advantages of DNA based 
vaccinations is the unlimited possibilities for encoding fusion proteins that both include 
targets and their subsequent adjuvants, allowing for the generation of a protein that did 
not previously exist but is both targetable and immune-stimulatory. Yet, despite these 
advantages, DNA vaccines have not been particularly potent in clinical trials55, likely due 
to the small amount of target antigen they produce, as well as the likelihood that naked 
DNA will be rejected instead of transcribed by the host machinery.   
Mechanisms of Action 
In terms of design, DNA vaccines often utilize a bacterial plasmid backbone, 
including hypomethylated CpG motifs. These motifs, along with other pathogen 
associated features of the bacterial backbone are able to induce strong innate immune 
responses at the site of vaccination, such as increased production of IL-6, IL-12, TNFα, 
IFNγ, IFNβ, and IFNα56,57. Originally, the innate immune response to DNA vaccines was 
thought to be driven by TLR9 signaling, which binds to hypomethylated CpG motifs, 
such as those in a bacterial or viral genome. However, recent studies have shown that 
DNA vaccines are equally potent in TLR9 knockout animals, and that the innate immune 
13 
 
response may instead be driven by cytoplasmic innate immune sensors such as STING or 
TBK-158. These features also help to polarize the resulting CD4+ T cell response to a Th1 
response, helping to ultimately generate effective CD8+ T cell responses.  
The molecular mechanism of DNA uptake and transcription are poorly 
understood, though methods of transfection, such as electroporation or utilization of a 
gene gun, have been found to increase efficacy of these vaccines59. Furthermore, which 
cell population transcribes and presents the proteins encoded by DNA vaccines is still 
unknown, though there are two main hypotheses that are currently being investigated. 
The first is that DNA vaccines directly transfect dendritic cells or other professional 
antigen presenting populations. Some evidence of this has been generated by the 
inclusion of survival factor plasmids in the initial transfection, theoretically prolonging 
dendritic cell life and capability for antigen presentation. In these studies, inclusion of a 
second plasmid containing the anti-apoptotic proteins BCL-Xl resulted in increased 
numbers of plasmid containing dendritic cells surviving in the draining lymph nodes 
following vaccination60. Furthermore, co-culture of dendritic cells from the draining 
lymph nodes of mice receiving both plasmids with naïve CD8+ T cells primed those T 
cells to produce significantly more IFNγ, suggesting that these dendritic cells were more 
potent inducers of CD8+ T cell immunity. One caveat of this study was the utilization of a 
gene gun, which is known to increase dendritic cell transfection when compared to naked 
DNA alone.  
The second possible hypothesis is that non antigen presenting cells at the site of 
vaccination form a type of antigen depot, which then undergoes apoptosis, and the debris 
is cross presented by professional antigen presenting cells, likely those of the CD8α+ 
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dendritic cell lineage. In support of this hypothesis, it has also been demonstrated that the 
inclusion of a Fas containing plasmid with a DNA vaccine plasmid increases both the 
concentration of the target protein in the draining lymph node as well as the resulting 
cytolytic function of whole splenocytes when anti-FAS antibody is included in the 
treatment scheme61. Other studies have shown that co-transfection of target antigen 
plasmids with a plasmid containing fully functional caspase 3 generated larger numbers 
of target specific CD8+ T cells as determined by ELISPOT62. Along with the Fas based 
studies, these data suggest that the plasmid containing cells needed to undergo cell death 
to provide functional immunity. Given the relatively nonspecific nature of these 
vaccinations, it is likely that both mechanisms play some role in the generation of an 
immune response though future research will be important in determining the exact 
functional mechanism of action. 
Fusion Proteins and Their Importance 
One of the primary disadvantages to DNA vaccinations is their relative 
inefficiency due to a large number of molecular steps between vaccination and the 
subsequent immune response to a specific protein.. Indeed, antigens must first be 
translated to a protein form, and then processed by professional antigen presenting cells 
to have any hope of generating an immune response. Morever, transfection efficiency is 
relatively low in vivo, due to the natural, anti-viral response that mammalian host cells 
have to foreign nucleic acids. The end result is low overall amounts of target protein 
being transcribed. To help enrich the target protein into professional antigen presenting 
cells, the tumor antigens in DNA vaccines may be fused to a protein that will help it 
home to professional antigen presenting cells63. For example, fusion of the hepatitis B 
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virus e (HBVe) antigen to a human IgG constant region results in significantly increased 
levels presentation of the HBVe protein in host dendritic cells, despite similar levels of 
transfection efficiency. Dendritic cells from mice receiving the fusion protein plasmid 
were more potent inducers of T cells responses when adoptively transferred into new 
hosts, suggesting that they may also be more mature64. Interestingly, other fusions of 
immune proteins have been shown to generate anti-tumor immunity in the setting of B 
cell lymphoma. In these models, the tumor and self-antigen idiotype of the B cell receptor 
(ID) is normally weakly immunogenic. However, when a DNA vaccine fusing CTLA-4 
to ID was administered prophylactically, ID specific T cell responses could be generated, 
and mice were protected from lethal tumor challenge. Furthermore, mutants of this fusion 
construct that could no longer bind CD80 or CD86 were no longer able to generate robust 
T cell responses to ID, suggesting that the generated fusion protein works by binding to 
antigen presenting cells and being internalized through receptor mediated endocytosis65. 
Many other fusion proteins have been found to localize target proteins into antigen 
presenting cells, including heat shock proteins66, molecules of the complement cascade 
pathway (C3d)67, or the β-defensin proteins68. 
Stimulatory Molecules and DNA Vaccines 
In addition to the use of fusion proteins, it is possible to include chemokines, or 
trafficking molecules to attract professional antigen presenting cells to the site of 
vaccination. As proof of principle, the addition of a plasmid encoding the chemokine 
MIP-1β to a DNA vaccine plasmid containing HIV gag protein resulted in significantly 
increased cellular infiltration at the site of vaccination, as well as the generation of 
protective immunity against GAG expressing Vaccinia Virus69. Additionally, inclusion of 
16 
 
a plasmid encoding CCL19 with the DNA vaccine plasmid encoding β-galactosidose has 
been found to stunt growth of the fibrosarcoma line MCA205 expressing β-galactosidose 
as a target antigen, as well as skew responding CD4+ T cells towards a Th1 phenotype70. 
Clinical Results 
Pre-clinical results with DNA vaccines were initially promising, though upon 
current review it is clear that these vaccines were predominantly tried in settings of 
lymphomas and other humoral immunity, which are historically easier to treat than solid 
tumors. Furthermore, many of these DNA vaccines were used prophylactically to prevent 
the implantation of cancer, which is not how they were going to be tested clinically. To 
date, several clinical trials have been done utilizing DNA vaccination platforms55, and all 
have confirmed safety of this approach, as well as the generation of an immunological 
response in the form of tumor specific CD4+ and CD8+ T cells, as well as formation of 
antibodies in response to the vaccination71–74. However, these clinical trials have had little 
effectiveness in the generation of potent anti-tumor immunity, possibly due to the 
difficulties of integrating foreign DNA into host cells, or of concentrating the target 
protein in the appropriate cell types. It is also plausible that the immunocompromised 
status of the patients receiving these trials makes it difficult to generate potent anti-tumor 
immunity, though other vaccine vectors have had more success with a similar patient 
population. 
Cell Based Vaccines 
Unlike DNA vaccines, which need to integrate into the host machinery for 
effectiveness, cell based vaccination strategies include all the machinery necessary for 
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protein translation and folding. Typically, cell based vaccine strategies follow a general 
regimen involving the in vitro manipulation of a cell population prior to introducing the 
newly modified cells to the patient as a vaccine. The type of cell used varies from 
genetically modified tumor cells, either from the patient or from a cell line, to protein 
pulsed and matured dendritic cells. In both settings, antigen dose is significantly higher 
than what is seen with DNA vaccines, and the generation of an immune response is not 
impaired by natural host aversion to the vaccine platform, as has been seen when trying 
to transfect cells in vivo with naked DNA. However, this vaccine type has its own set of 
disadvantages. First off, and perhaps most importantly, cell based vaccination strategies 
are poorly immunogenic when compared to live-attenuated vaccines. Cell based 
vaccination strategies are missing adjuvant and pathogen associated molecular patterns, 
as they are not derived from pathogens. As such, it may be difficult for them to break 
tumor induced tolerance to certain antigens. Furthermore, since they are live cells, 
production, maintenance, and storage all require increased levels of technical expertise 
and cost. Finally, some cell based vaccines utilize the patient’s own cells, either tumor 
cells modified to become immunogenic, or immune cells modified to stimulate a potent 
CD8+ T cell response. These strategies provide individualized treatment to patients, but 
take exponentially more time, technical expertise, and funding to develop and use. Yet, 
despite these disadvantages, two cell based vaccine strategies have seen promising 
clinical results; namely GVAX and Sipuleucel-T.  
Cancer Cell Based Vaccines: GVAX 
Early in cancer immunotherapy, few tumor associated antigens had been 
identified, and even today, the number of tumor associated antigens identified likely pales 
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in comparison to the number of mutations being expressed by an individual tumor. 
Therefore, to circumvent the need to identify an individual target, whole cell vaccines 
were investigated. However, as stated previously, due to immune editing, many cell lines 
were poorly immunogenic, like clinical disease. Yet, it stood to reason that it was 
possible to modify these tumor lines in vitro to restore their immunogenicity, perhaps 
through the production of stimulatory cytokines. Therefore, Dranoff et. al performed a 
seminal study that introduced overexpression of different stimulatory cytokines into the 
melanoma cell line B16-F10, which was known to be poorly immunogenic75. After a 
heavy dose of radiation, the now cytokine expressing tumor lines were reintroduced to 
the host animals as a vaccine against the parental tumor cell line. Of the cytokines 
examined, GM-CSF generated the most potent anti-tumor immunity. These 
groundbreaking results were directly responsible for the generation of many different 
tumor lines, all expressing GM-CSF76–79. Today, the process of overexpressing GM-CSF 
in a tumor line, subsequent irradiation, and reintroduction into a host as a vaccine is 
known as GVAX80,81.  
Mechanism of Action 
 GM-CSF is a cytokine that has been shown to induce the generation of potent 
antigen presenting cells82, though more recent studies suggest that GM-CSF treatment 
may selectively expand certain subsets of dendritic cells more than others83. GM-CSF 
produced by tumor vaccinations results in increased dendritic cell trafficking to the site of 
vaccination, as well as increased expression of maturation markers on dendritic cells84. 
Therefore, when the GM-CSF producing tumor cells that have been reintroduced undergo 
apoptosis due to extensive radiation damage, these cells will release danger signals, 
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which, along with tumor antigens, will be picked up by the newly recruited dendritic 
cells. Indeed, vaccination with GM-CSF secreting tumor cells has been found to increase 
dendritic cell infiltration of tumors, as well as provide protective immunity against 
rechallenge with parental B16-F1084. Interestingly, GM-CSF secreting tumors seemed to 
expand out the CD8α− dendritic cell subset in the spleen, and these cells expressed 
increased levels of CD80, and CD1d, suggesting increased maturation. Finally, the 
potency of the GVAX approach is not limited to melanoma cell lines, but has been 
preclinically confirmed in many different types of cancer, including lymphomas, 
leukemias, mammary carcinomas, and colon carcinomas to name few76–79,85. 
Clinical Results 
Clinically, several phase I and phase II trials have been completed and reported 
utilizing autologous vaccination strategies80. In these trials, including patients with 
melanoma, prostate cancer, and non-small cell lung cancer, the majority of patients had 
delayed type hypersensitivity reactions, as well as cellular infiltration of the vaccination 
site by dendritic cells, macrophages and eosinophils86–88. Furthermore, in trials designed 
to study efficacy of the vaccines, approximately 20% of patients showed either stable 
disease or mixed responses, suggesting that this approach could have significant 
therapeutic potential.  
In the early GVAX trials, development of the vaccine platform, namely the 
creation of a GM-CSF secreting autologous tumor line from the patient’s own resected 
tumor, took between eight to ten weeks. During this time, many patients had their disease 
progress, and become subsequently ineligible for vaccination. Therefore, the 
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development of an allogeneic, off-the-shelf treatment utilizing the GVAX platform was 
developed. While the specificity to the patient was lost, many tumor antigens are shared 
within a tumor type, and some universal antigens have been found across tumor types, 
thus still maintaining the potential for a multi-antigen response. Therefore, allogeneic 
GM-CSF secreting lines were developed and tested clinically. One of the early studies in 
pancreatic cancer found that vaccination following surgical resection increased survival 
by about 5 months when compared to historical controls. Another study in pancreatic 
cancer did not find a survival benefit, but did find that 38 out of 43 patients analyzed 
generated CD8+ T cell responses to at least one new mesothelin peptide89. Yet another 
study, using a Her2+ breast cancer GVAX vaccine, found that combinations of GVAX 
with cyclophosphamide treatment could generate HER2 specific antibody responses in 
32% of patient treated90. Together, these data showed promising results through the use 
of genetically modified whole cell vaccines, and confirm that the immune system is 
capable of responding to tumor antigens, when shown them in the proper context.  
Dendritic Cell Based Vaccines: Sipuleucel-T 
Another type of cell based vaccination involves the modification of not the tumor 
cells, but of the patients own dendritic cells91. In this vaccine, lymphocytes are removed 
from the patient’s blood, before being cultured in vitro in the presence of target antigen as 
well as a maturation stimulus. This matures and expands the population of dendritic cells, 
and loads them with a specific target before they are infused back into patients. This 
method provides the functional antigen presenting population necessary for the 
generation of an adaptive immune response. There are several advantages to the use of 
dendritic cells for a cell based vaccine. One of the major advantages is that in vitro 
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manipulation of the dendritic cells directly bypasses any potential for inadequate 
dendritic cell activation, be it due to suboptimal dosing, or lack of pattern associated 
molecular patterns in vivo. Furthermore, it also allows for easy manipulation of the target 
antigen, simply by adding a different antigen to the in vitro mix. However, this vaccine 
strategy is only capable of mounting a single-antigen immune response, specifically 
directed at the target protein. This contrasts with GVAX based approaches, where the 
whole proteome of the tumor is presented in a vaccination context. Also, as was seen in 
the autologous GVAX approaches, the use of a single patients own dendritic cells 
requires high levels of technical expertise, as well as special care in handling, culturing, 
and storing. This increases both the time and cost associated with this type of vaccine. 
Finally, this approach requires the patients to have a healthy enough dendritic cell 
population to successfully culture a response in vitro, which may prove difficult in some 
older, more immunocompromised patients.  
Mechanism of Action 
 Early work in preclinical models found that isolation of dendritic cells, ex vivo 
antigen pulsing and maturation, and subsequent reinjection of those dendritic cells into 
their original hosts resulted in the generation of potent anti-tumor immunity in a variety 
of models, including B cell lymphoma, fibrosarcoma, breast carcinoma, and lung 
carcinomas92–94. To generate protective immunity using this strategy, dendritic cells are 
crucial as pulsing other cell types, such as B cells, has no vaccination benefit92. 
Furthermore, transfer of peptide loaded dendritic cells can generate tumor specific 
antibodies92, as well as CD4+ and CD8+ T cell responses93,94, resulting in tumor lysis. 
Finally, dendritic cell vaccines have also been found to produce anti-tumor immunity in 
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established tumors, when treated in vitro with GM-CSF and acid eluted, unfractionated 
peptides from resected tumor95. In this model, it would actually be possible to mount a 
multi-epitope immune response. When utilizing dendritic cell vaccines, CD4+ and CD8+ 
T cells are required for the generation of anti-tumor immunity, and transfer of sera does 
not provide protection. Furthermore, blockade of CD28 signaling by the administration of 
a CTLA4-IG fusion protein with the dendritic cell vaccine prevents therapeutic effect95. 
Together, these data suggest a model by which dendritic cells are functionally matured in 
the presence of target antigens in vitro. During this maturation process, co-stimulatory 
signals, such as CD80 and CD86 are generated, providing both signal one, in the form of 
target antigen, and signal two, in the form of co-stimulatory molecules. Together, these 
signals result in the generation of a potent T cell response, which has been found to be 
critical for the rejection of solid tumors. The culmination of these preclinical data was the 
development of the clinical treatment, Sipuleucel-T. 
Clinical Results 
Clinically, Sipuleucel-T, also known as Provenge, was the first cancer vaccine 
approved by the FDA, making it a landmark treatment for minimally symptomatic 
metastatic castration-resistant prostate cancer (CRPC). Broadly, this vaccine involves the 
removal of the patient’s dendritic cells from peripheral blood, followed by in vitro 
treatment with a fusion protein combining GM-CSF with the tumor associated antigen, 
Prostatic Acid Phosphatase (PAP). Following in vitro treatment, these dendritic cells are 
transferred back into their original host. In three clinical trials, Sipuleucel T was found to 
extend the lives of patients by about 4 months96,97,98, though statistical significance was 
not reached in the first trial. Furthermore, as was seen in the preclinical data, PAP 
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specific T cell responses were generated by this vaccine in about 28% of patients treated, 
further validating the scientific rationale behind these treatments.  
Live, Attenuated Vaccine Vectors 
The last category of cancer vaccine is known as a live-attenuated vaccination. As 
the name would suggest, these vaccines are metabolically active, though weakened, 
pathogenic vectors. Many vaccinations currently utilized in the clinic fall into this 
category, including the vaccinations for mumps, measles, and chickenpox. To generate 
viral live-attenuated vaccines, wildtype viruses are repeatedly grown in suboptimal 
culture conditions, including cells they replicate poorly in, selecting for viral products 
that grow better in these suboptimal conditions and subsequently weakening their 
virulence in the original host. Bacterial live-attenuated strains are produced through the 
directed deletion of certain genes in the bacterial genome99. Perhaps the most important 
advantage of live-attenuated vaccines when compared to the previous two types is that 
live-attenuated vaccinations are the most foreign vector. Thus, these vaccines are capable 
of generating potent cellular and humoral immunity, and clinically, are typically potent as 
a single dose vaccination for life. Like the DNA vaccines, live-attenuated vaccines can 
also be easily genetically modified to include target antigens or stimulatory proteins. 
Additionally, live-attenuated vaccines can be made into off-the-shelf therapies, and are 
translatable into large scale production. Yet, since the viral or bacterial vector is foreign, 
live-attenuated vaccines can only present a limited number of pre-selected targets. 
Furthermore, introduction of some targets in bacterial vaccine vectors can affect their 
potency as the lifecycle of the bacteria is interrupted. Live-attenuated vaccines also have 
a unique disadvantage, in that they are still virulent, and have the potential to replicate 
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and infect their host. This has often been addressed by the use of inactivated vaccinations, 
where the vector is killed either through chemical treatment, heat, or radiation. While 
killed vaccines have no pathogenicity once killed, they also stimulate a weaker immune 
response, and generally require booster treatment to generate fully protective immunity. 
Finally, one unique property of live-attenuated vaccines, that can be either an advantage 
or disadvantage, is that the mechanism of action will be unique to each individual vector. 
Therefore, the potency of one target antigen in a certain live-attenuated vector, such as 
Vaccinia Virus, may be completely different from the potency of that same target in a 
different vector, such as Listeria Monocytogenes. 
Vaccinia Virus Vectors 
Vaccinia Virus, a member of the poxvirus family100, is a double stranded DNA 
virus that has been one of the major success stories in the field of Immunology, and its 
widespread use is largely responsible for the eradication of smallpox. As with many other 
live-attenuated vaccines, Vaccinia Virus was generated by passaging the parental virus 
through a series of hostile culture conditions, resulting in a strain of virus that is 
metabolically active, but grows poorly in humans (and mice). In vivo, our group and 
others have shown that Vaccinia Virus given intravenously is likely presented to the 
adaptive immune system only by CD8α+ conventional dendritic cells101. However, 
despite its attenuated status, the adaptive immune response, specifically CD4+ T cells, is 
crucial to the clearance of Vaccinia102.  
 Mechanistically, Vaccinia Virus has also been found to produce a series of 
proteins that interfere with the immune response being generated. Once in the cell, 
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Vaccinia produces viral protein A46, stopping the infected cell from recognizing its 
infection by binding signaling adaptor proteins of the TLR and RLR signaling pathway 
through its TIR domain103,104.  A46 can bind MYD88, MAL, TRIF105, and TRAM, 
preventing TLR signaling, among other innate pathways, from responding to the 
infection. Viral protein A52 binds to IRAK and TRAF6 signaling proteins interfering 
with downstream NFkB activation103,106, while protein K7 inhibits viral recognition 
pathways from producing IFNβ107. These proteins, along with a series of other viral 
products108 modify the immune system’s capability to respond to Vaccinia. These 
interactions with the immune system are likely what makes different live-attenuated 
vaccination vectors different in terms of the generation of adaptive immunity. 
Due to its foreign and infectious nature, Vaccinia is capable of generating a strong 
immune response. It is also fairly easy to genetically manipulate, making it a good vector 
for the addition of tumor associated antigens. A variety of clinical tumor associated 
antigens have been added to a Vaccinia Virus vector, including Carcinoembryonic 
Antigen (CEA)109–111, Prostate Specific Antigen (PSA)112–114, melan-A/MART-1, 
Tyrosinase, and gp100115,116. In each of these trials, Vaccinia based vectors were able to 
induce tumor associated antigen specific CD8+ T cell responses as well as antibodies 
against the targeted protein. However, the clinical results were often limited to stable 
disease in the best case. Of note, when Vaccinia Virus was used as a vector to immunize 
against the E2 protein of HPV, remarkably 34 out of 36 patients treated showed 
elimination of precancerous lesions, along with the generation of HPV E2 specific 
antibodies, and a significant reduction in HPV viral load117. These data suggest that 
Vaccinia may be a good live-attenuated vector for vaccination against other viruses, such 
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as HPV. In the case of HPV+ cancers, viral proteins are capable of driving uncontrolled 
cell division, and thus, clearance of the virus is often directly correlated with regression 
in these settings. However, the question remains why Vaccinia vector based vaccination 
seem to produce CD8+ T cell responses that are incapable of tumor rejection in clinical 
diseases that are not driven by chronic infection.   
Listeria Monocytogenes Vectors 
Listeria Monocytogenes is a gram positive, rod shaped, intracellular bacteria. 
Similar to Vaccinia, in vitro, Listeria is capable of infecting a wide variety of cell types. 
Nevertheless, early research utilizing Listeria Monocytogenes as a model pathogen 
demonstrated that the deletion of the CD11c+ conventional dendritic cell population 
significantly decreased the resulting CD8+ T cell response118. Further research has shown 
the CD8α+ dendritic cells are required for Listeria Monocytogenes, given intravenously, 
to enter the spleen119,120. However, the exact cell type responsible for priming the 
adaptive immune response has not been fully elucidated. In terms of the molecular 
response, Listeria Monocytogenes is known to be recognized by the TLR2121, TLR4, 
RIG-I122,123, STING124, and NOD-like125 pathways. Each of these pathways has been 
shown to be critical to the clearance of wild type Listeria, though none are required for 
the production of IFNβ that is a hallmark of Listeria infection126. However, production of 
IFNβ does require interferon response factor 3 (IFR3) and Tank Binding Kinase-1 (TBK-
1)127–129, though it is possible that all the above mechanisms result in IRF3 and TBK-1 
signaling, and thus overlap to sense intracellular Listeria. Furthermore, myeloid dendritic 
cells only produce IFNβ when the Listeria being used is metabolically active130, 
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suggesting that one of the key mechanisms to the generation of an immune response to 
Listeria is the pathogen’s ability to get into the host cell’s cytoplasm.  Further supporting 
this hypothesis is the fact that mice with the type I interferon receptor knocked out are 
resistant to Listeria infection131. 
To avoid the immune system, Listeria has also developed a series of proteins that 
allow it evade the normal immune response during its lifecycle. Following uptake into an 
endocytic vesicle, the bacterium expresses Listeriolysin O, which is a pore forming 
protein that allows the Listeria to avoid degradation in the vacuole. LLO is maximally 
active at a pH of 5.5132, allowing for the bulk of its activity to occur within the acidic 
endosomes of host cells, without punching holes in the cell’s plasma membrane. After 
lysing the endosome, the bacterium is released into the cytoplasm of the infected cell, 
where it would normally be targeted by the autophagocitic machinery of the host cell. To 
prevent this, Listeria has a protein named Actin Assembly-inducing Protein A (ActA), 
which acts as a molecular mimic of the Wiskott-Aldrich Syndrome Protein, recruiting the 
host Actin-Related Protein 2 and 3 complex (Arp2/3) to form actin tails133. The force 
generated by the assembly of actin tails push the bacterium throughout the cell, 
preventing autophagy134. Furthermore, actin tails allow for the bacterium to travel from 
the initially infected cell into neighboring cells, allowing for the spread of infection 
without exposing the bacteria to the extracellular environment. Finally, the process of 
bacterial spreading is enhanced when the neighboring cells are producing nitric oxide, 
suggesting that Listeria may have adapted to thrive in the midst of an immune 
response135. Unlike Vaccinia, which seeks to hide from the immune system through the 
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inhibition of activation pathways, Listeria seems to benefit from the generation of an 
immune response and instead has found molecular mechanisms to escape rejection. 
In the wildtype form, Listeria infections can be cleared by healthy hosts in a 
manner that depends on the formation of an adaptive immune response. However, as 
previously discussed, Listeria also has a variety of mechanisms to avoid the immune 
system, and so must be modified prior to its use as a vaccine. Fortunately, like Vaccinia, 
Listeria has been found to be amenable to genetic modification. By knocking out the 
bacterial proteins ActA and Internalin B (IntB), the virulence of a Listeria vector is 
decreased 1000 fold when compared to the wild type bacteria136. With these two genes 
deleted, the Listeria vaccine vector is more likely to enter phagocytic cells, such as a 
dendritic cells or macrophages, and the bacterium can no longer spread between cells, 
limiting its infectious potential. Preclinically, a number of target tumor associated 
antigens have been added to this live-attenuated Listeria vector, including HPV16 E7137, 
PSA138, and the melanoma antigen TRP-2139. In these models, Listeria based vectors have 
been found to generate CD8+ T cells capable of producing IFNγ. with limited antibody 
formation. This is potentially relevant, since it limits the likelihood of neutralizing 
antibody formation and provides scientific rationale for repeat dosing to generate the 
most potent anti-tumor immunity. Additionally, anti-tumor immunity had been found in 
both prophylactic and therapeutic settings, and protective memory responses were 
generated. Finally, previous work from our group has shown the Listeria based vaccines 
provide enough stimulation to rescue CD8+ T cell responses to self-proteins, including 
increased divisions and cytolytic function, as well as the generation of increased effector 
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cytokines (Goldberg, unpublished data). These data demonstrate that live-attenuated 
Listeria vectors are capable of breaking tolerance to self, and potentially to tumors. 
Clinically, a trial testing the safety of the live-attenuated Listeria vector has just 
completed140. This trial represents the first trial in which the Listeria vector had both the 
ActA and IntB genes knocked, though previous trials have been done using a Listeria 
vector with LLO knocked out141. From this trial, all tested doses of this strain of Listeria 
were well tolerated, and 37% of the initial testing cohort survived >15 months, and long 
term survival correlated with development of an immune response to the vaccine140. In 
both these studies, Listeria vaccination induced both T cell responses capable of 
producing IFNγ in response to both Listeria derived antigens as well as the target antigen 
being examined. While this study was not powered to test survival, these are promising 
results for initial studies. 
Summary 
The adaptive immune system is extremely powerful, and able to discriminate 
between targets at the molecular and cellular level. Moreover, the immunity that is 
generated is often sterilizing, and provides lifelong protection in the form of memory. 
Research has shown that the immune system can recognize and reject cancer, and may do 
so more often than previously thought. However, by the time of a clinical diagnosis, the 
immune system has been rendered tolerant to the tumor, either through the absence of 
cells capable of rejecting the tumor, or their subsequent tolerization. Cancer vaccinations 
represent a clinical strategy by which new immune responses can be generated against 
the tumor, or existing ones can be boosted. On the other hand, monoclonal antibody-
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mediated blockade of checkpoint proteins can be used to reverse tolerance and maintain 
anti-cancer responses once they have been initiated. Realistically, optimal 
immunotherapy treatments for cancer will likely be a combination of these two strategies, 
where checkpoint blockade is utilized to amplify and protect a developing immune 
response from cancer derived tolerance.   
However, questions still remain about why certain cancer vaccines are more 
effective than others. What are the effects of different vaccines on dendritic cells, and 
how do these differences translate into different CD8+ T cell responses? Do differences in 
dendritic cell responses correlate with anti-tumor immunity, and can these differences be 
utilized to design the optimal anti-cancer vaccine? How do different vaccine vectors 
affect checkpoint protein expression, and how can this knowledge be manipulated to 
ensure maximal anti-tumor immunity? Future research will be necessary to identify the 
molecular determinants in the professional antigen presenting cells that control the 
potency and characteristics of the adaptive immune response. In this work, we identify 
the differences in responding antigen presenting cells responsible for generating an 
adaptive immune response to both Listeria and Vaccinia. Furthermore, we identify the 
fact that these differences have significant effects on the resulting CD8+ T cell 
population, and how those molecular differences may generate different functional 
outcomes in terms of anti-tumor immunity. Finally, we identify a previously unknown 
function of live-attenuated Listeria vaccines, whereby the vaccine allows for CD8+ T cell 
activation without PD-1 expression. Together, these data show the important potential for 
overlap between checkpoint blockade and vaccines. Indeed, the effects of any vaccine 
vector on checkpoint protein expression need to be evaluated carefully to determine if 
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checkpoint protein status correlates with anti-tumor function, both preclinically as well as 

















 Mice were kept and used in accordance with guidelines of the Johns Hopkins 
University Institutional Animal Care and Use Committee.  All mice used were female 
mice between 8-16 weeks old. Female B6-Ly5.2 (also known as CD45.1) congenic mice 
were obtained from the National Cancer Institute at Fredrick. Rag2-/- mice on the 
C57/BL/6 background were purchased from Jackson Laboratory (Bar Harbor, Maine). 
OVA specific, OT-1 mice on a C57BL/6 (H-2b) background were originally obtained 
from Dr. M. Bevan (University of Washington, Seattle, WA), and were bred at JHU onto 
a Rag2-/- background. HA specific, Clone 4 Thy1.1+ mice were originally obtained from 
Dr. Linda Sherman (Scripps Research Institute, La Jolla, CA). PD-1-/- mice on a C57/B6 
background were provided by Dr. Lienping Chen (Yale University, Connecticut, MA) 
with permission from Dr. T. Honjo (Kyoto University, Kyoto, Japan). B10.D2 Thy1.2+ 
mice were originally purchased from Jackson Laboratory (Bar Harbor, ME) and were 
subsequently bred and maintained at JHU. C3-HAlo mice were generated originally in our 
lab142, and express Hemagglutinin driven by the rat C3 promoter, which has been found 
to be one of the subunits of the oligiomeric prostatic steroid binding protein. The 
resulting mouse expresses HA at detectable mRNA levels in the lungs, muscle, heart, 
pancreas, salivary gland, as well as the prostate and testes. These mice express about 15x 
less HA than the C3-HAhi mouse. Despite decreased expression of HA, C3-HAlo mice 
provide a tolerizing environment for HA specific CD8+ T cells, and were therefore used 
as a control for a non-inflammatory condition in these experiments. CAG-OVA mice 
were purchased from Jackson Laboratories (Bar Harbor, Maine). Briefly, these mice 
express Ovalbumin under the control of the β-actin promoter, resulting in ubiquitous 
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expression of Ovalbumin throughout the mouse, and providing for a non-inflammatory 
condition for OVA specific CD8+ T cells. MyD88-/- mice were originally created through 
the addition of a LoxP site to either side of exon 3 of the MyD88 gene, followed by 
subsequent breeding to a mouse expressing Cre protein in germ line cells. These mice 
were a generous gift from Dr. Franck Housseau (Johns Hopkins University, Baltimore, 
MD). STING KO mice, otherwise known as Golden Ticket mice, were generously 
provided by Dr. Young Kim (Johns Hopkins University, Baltimore, MD), who originally 
received these mice from Dr. Russell Vance(UC Berkley, Berkley, CA)143. Briefly, these 
mice were generated through mutagenesis with N-ethyl-N-nitrosourea, during which a 
single nucleotide variant T596A in the STING gene occurred, resulting in no detectable 
production of the STING protein143. 
Buffers 
 Unless otherwise stated, all cell culture was performed in RPMI 1640 (Corning, 
Manassas, VA) supplemented with 10% fetal bovine serum (Gemini Bio Products, 
Sacramento, CA), 1 moll MEM sodium pyruvate (Sigma, St. Louis, Missouri) 0.1 mM 
MEM nonessential amino acids, 1000 IU penicillin, 1000 IU streptomycin (Lifescience 
Technologies, Grand Island, New York), 4.5 × 10−5 M 2-ME (Lifescience Technologies, 
Grand Island, New York). Henceforth, this combination is referred to as “complete 
RPMI.” Miltenyi isolations and extracellular staining were performed in MACs buffer. 
To make MACs buffer, 2mM EDTA (Lifescience Technologies, Grand Island, New 
York) and 0.5% Bovine Serum Albumin (Roche, Mannheim, Germany) were added to 
PBS (Lifescience Technologies, Grand Island, New York). For intracellular staining, 
cells were fixed using Fix/Perm (Ebioscience, San Diego, CA) kit and stained in Perm 
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Buffer (Ebioscience, San Diego, CA), which were both generated from concentrate 
according the manufacture’s protocol. In the lung harvest experiments, lungs were fixed 
and bleached using Fekete’s Solution, which is made by combining the following: 
580mLs 95% ethanol, 200mL H2O, 80mLs of 37% formaldehyde solution, and 40mLs of 
glacial acetic acid. 
Cell Lines and Vaccines 
 Both B16-OVA and EL4-OVA were a generous gift from Dr. Hyam Levitsky. 
Breifly, to generate these cell lines, the parental strains EL4144 and B16145 were 
electroporated or lipofected, respectively, with a plasmid construct containing the whole 
chicken ovalbumin gene under the control of the human β-actin promoter, as well as 
resistance genes to G418 and neomycin for selection. To preserve OVA expression both 
B16-OVA and EL4-OVA were both grown in complete RPMI media supplemented with 
0.5mg/mLG418 prior to implantation. Listeria expressing OVA protein was a generous 
gift from Dr. Pete Lauer at Aduro Biotech. Briefly, live attenuated strains of Listeria 
were generated from the 10403s strain by in-frame deletions of the ActA and IntB, and 
the subsequent addition of an OVA expressing cassette under the control of the LLO 
promoter. Other strains of Listeria utilized the same OVA expression cassette, but 
contained different gene knockouts. For experiments on the B10.D2 background, 
attenuated Listeria expressing the HA peptide specific for CD8+ T cell responses 
(IYSTVASSL) were used, and driven under the LLO promoter. Listeria were grown in 
brain-heart infusion media and harvested mid-log phase growth, purified by standard 
methods, and stored at a concentration of >1x1010 CFU per mL at -80°C as single use 
stocks. Vaccinia Virus expressing the target antigens HA or OVA were expanded on Hu-
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TK- cells, concentrated via ultracentrifugation, and titered by a plague assay on BSC-1 
cells. Vaccinia viral particles were then frozen at a concentration of 5x106 pfu per mL, 
and stored at -80°C as single use stocks. 
Flow Cytometry Antibodies 
Antibodies used in these studies include: CD8 Pacific Orange – Clone 5H10 
(Invitrogen, Grand Island, New York), Ly6G Brilliant Violet 421 – Clone 1A8 
(Biolegend, San Diego, CA), LAG-3 eflour 450 – Clone C9B7W (Ebioscience, San 
Diego, CA), CD45.2 Pacific Blue – Clone 104 (Biolegend, San Diego, CA), CD49b 
Alexaflour 488 – Clone DX5 (Biolegend, San Diego, CA), CD69 FITC – Clone H1.2F3 
(BD Pharmigen, San Jose, CA), Thy1.2 FITC – Clone 53-2.1 (BD Pharmigen, San Jose, 
CA), TNFα eflour450 – Clone MP6-XT22 (Ebioscience, San Diego, CA), CD19 PE - 
Clone eBio1D3 (Ebioscience, San Diego, CA), granzyme B – Clone 16G6  (Ebioscience, 
San Diego, CA), Egr2 PE – Clone erongr2 (Ebioscience, San Diego, CA), Ly6C 
PerCp/Cy5.5 – Clone HK1.4 (Biolegend, San Diego, CA), CD160 PerCp/Cy5.5– Clone 
CNX46-3 (BD Pharmigen, San Jose, CA), PD-1 Pe-Cy7 – Clone J43 (Ebioscience, San 
Diego, CA), Tbet Pe-Cy7 – Clone eBio4B10 (Ebioscience, San Diego, CA), IFNγ Pe-
Cy7 – Clone XMG1.2 (Biolegend, San Diego, CA), CD11c APC – Clone HL3 (BD 
Pharmigen, San Jose, CA), IL-2 APC – Clone JES6-5H4 (BD Pharmigen, San Jose, CA), 
Thy1.1 APC – Clone HIS51 (Ebioscience, San Diego, CA) CD11b AF700 – Clone 
M1/70 (Biolegend, San Diego, CA), and CD3ε APC-Cy7 – Clone 145-2C11 (Biolegend, 




Extracellular Staining and FACS sorting 
 Cell staining was done as previously reported. In brief, prior to staining, CD8+ 
cells were enriched using magnetic bead enrichment prior to staining. About 5x106 CD8+ 
cells were resuspended directly ex vivo in MACS buffer in a 96 well plate, before being 
resuspended in a 50µL of a mix of MACS buffer containing either the combination of 
antibodies or single stain controls for compensation. Cells were incubated at room 
temperature for 15 minutes in the dark, before excess antibody was washed off with 
MACS buffer. If cells were not being intracellularly stained, they were resuspended in 
MACs buffer and run fresh on a FacsCaliber or LSRII flow cytometer (BD, San Diego, 
CA). For FACS sorting, cells were stained sterilely as above, but were then sorted on a 
FacsAria (BD, San Diego, CA) into complete RPMI media. Following cell sorting, cells 
were recounted before being used in further experiments. 
Intracellular Staining 
For intracellular cytokine staining, cells were restimulated in vitro for 5 hours at 
37°C with 10µM OVA (SIINFEKL) or 10µM HA (IYSTVASSL) peptide in the presence 
of protein transport inhibitor cocktail (Ebioscience). After five hours, cells were washed 
with MACs buffer, and stained extracellularly (see above). Following the extracellular 
stain, cells were fixed overnight using 100µL Fix/Perm buffer. The following day, cells 
were washed in Perm buffer, and resuspended in a 50µL of a mix of Perm buffer 
containing either the combination of antibodies or single stain controls for compensation. 
Cells were incubated at room temperature for 20 minutes in the dark, before excess 
antibody was washed off with Perm buffer. Cells were then resuspended in MACs buffer 
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and run on a FacsCaliber or LSRII flow cytometer (BD, San Diego, CA). For 
transcription factor staining, cells were not restimulated for 5 hours, but were instead 
stained directly ex vivo. 
Data Analysis and Statistics 
 All data presented, with the exception of pie charts, were generated using FlowJo 
software (Treestar, Ashland, OR) or Graphpad Prism software, version 5.0c (GraphPad 
Software, La Jolla, CA). Pie charts presented were generated using Microsoft Excel 2011. 
Summary statistics are all presented as the mean +/- the standard error of the mean. 
Group means were compared using two sample student T tests, while event free survival 
was examined with the Kaplan-Meir method. All p-values are two-sided, and statistical 














LISTERIA MONOCYTOGENES BASED VACCINES PROVIDE FOR 






 The generation of a potent, specific immune response to cancer is one of the 
driving goals of research in the field of Immunology. To this end, a variety of cancer 
vaccine vectors have been developed, as described above, in the hopes that a vaccine will 
re-start the immune system, and allow, ultimately, for tumor rejection and the generation 
of lifetime protective immunity. However, as several platforms of live-attenuated 
vaccines have been generated, it has become clear that some platforms result in better 
tumor rejection than others. The reason for these different efficacies is not particularly 
well understood on the cellular and molecular levels. Why some vaccines generate more 
potent CD8+ T cell responses than others is a question that will require further 
investigation, and is the subject of this research. In this chapter, we will introduce the 
difference in anti-tumor efficacy generated by two different vaccine vectors; Listeria 
Monocytogenes and Vaccinia Virus. Both of these vectors are live-attenuated vaccines, 
which have been genetically engineered to express ovalbumin as an example tumor 
associated antigen. In the case of Listeria, the genes IntB and ActA were genetically 
deleted prior to use as a vaccine. 
Chapter Specific Materials and Methods 
Tumor Growth Experiments 
 Tumor implantation experiments all followed the same schedule. On day 0, 1-
1.5x105 B16-OVA or EL4-OVA cells were implanted subcutaneously on the right flank 
of host mice. On day 3, host mice received intravenous vaccinations via tail vein 
injections of PBS, 1x107 cfu Listeria-OVA cfu, or 1x106 pfu Vaccinia-OVA. All 
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vaccinations were given in 200µL PBS. Tumor growth was measured as previously 
described using engineering calipers45. Briefly, tumors were measured every 2-3 days, 
and tumor size was reported as volume using the formula tumor volume=m1 x m2 x (π/6).  
For metastatic lung burden models, 1-1.5x105 B16-OVA cells were filtered through a 
70µm nylon mesh filter before being injected via tail vein injection in 200µL PBS. On 
day 3, mice were treated in the same manner as the subcutaneous model. For 
measurement of metastatic burden, host animals were sacrificed on day 18-20, and lungs 
were fixed in Fekete’s Solution overnight. After fixation, lungs were transferred to PBS, 
and spots were counted using a dissecting microscope. For survival experiments, animal 
survival was monitored following vaccination, and animals were euthanized if they 
displayed hunched behavior along with ruffled fur and heavy breathing. 
CD8+T Cell Depletion 
 Depletion of CD8+ T cells was achieved by repeated intraperitonial 
administration of 200µg of 2.43 antibody (Harlan Laboratory, Dublin, VA). Mice 
received depleting antibody on Days -7, -5, -3, -1, 2, 7, and every 7 days to maintain 
depletion. On day -4, peripheral blood from depleted or undepleted mice was checked for 
the presence of CD8+ T cells by flow cytometry. Tumor growth experiments were 
repeated as previously, with depleted animals receiving i.v. tumor on Day 0 and 






Listeria Based Vaccination Provides Superior Anti-Tumor Immunity in Both 
Subcutaneous and Metastatic Models 
 To test the hypothesis that vaccinations can provide anti-tumor immunity, we 
utilized a model antigen system that would allow us to examine the effects of our 
vaccinations in an antigen specific manner. Here, the expression of OVA by cancer cells 
is intended to model a unique tumor antigen, like a mutated protein expressed solely in 
tumor tissue. Significant research has been done to identify a variety of unique tumor 
antigens146, since these antigens represent targets that the host will not tolerize responses 
to through normal peripheral tolerance mechanisms. Additionally, by targeting unique 
tumor antigens, it is possible to separate anti-tumor immunity from the development of 
autoimmunity. After receiving subcutaneous implantation of either B16-OVA (Fig 3-1a) 
or EL4-OVA (Fig 3-1b) on day 0, host mice were vaccinated on day 3 with either 
Listeria-OVA or Vaccinia-OVA intravenously, and tumor growth was measured over 
time. While both vaccinations did delay tumor growth, Listeria-OVA provided superior 
reduction of tumor growth in both models.  Furthermore, no adoptive transfer was 
utilized, suggesting that both vaccines are capable of generating an anti-tumor immune 
response from the host’s endogenous cell population. 
 To further examine the potential for these vaccines, we proceeded to test their 
efficacy in a metastatic model by giving B16-OVA intravenously on day 0 instead of 
subcutaneously. In this model, the lungs provide a good readout for overall tumor burden. 
As was seen in the flank models, Vaccinia-OVA did generate an anti-tumor effect, 
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resulting in decreased size and number of metastatic spots on the lungs. However, the 
Listeria-OVA vaccinated animals had significantly lower tumor burden, though some 
micro-metastases could still be detected under a dissecting microscope (Fig 3-2b, c). The 
significant decrease in tumor burden was reflected in the overall survival of these 
animals, as Listeria-OVA vaccination showed the greatest increase in median survival 
(Fig 3-2a). Together, these data demonstrate that the Listeria vaccine vector was more 
potent in the generation of anti-tumor immunity, despite targeting the same antigen as the 
Vaccinia vaccine. 
Protective Immunity Generated by Either Vaccination is Dependent on                          
the Generation of an Adaptive Immune Response 
 Since vaccinations can be effective in reducing tumor burden either through 
oncolytic mechanisms or through the generation of an immune response, we wanted to 
test the hypothesis that the anti-tumor response seen as a result of these vaccines was 
dependent on the adaptive immune system. To explore this question, we injected RAG2-/- 
mice with B16-OVA intravenously, and then proceeded to vaccinate them with PBS, 
Listeria-OVA, or Vaccinia-OVA, and examined their overall survival. In these animals, 
loss of RAG2 results in the absence of B cells, T cells, and NKT cells, thus no adaptive 
immunity can be developed. Surprisingly, the Vaccinia-OVA vaccinated animals showed 
a decrease in overall survival as seen in Figure 3-3. Upon closer examination, Vaccinia 
vaccinated mice had symptoms consistent with fatal Vaccinia challenge, including skin 
sores and tail decay, highlighting some of the potential risks of a live-attenuated vaccine. 
In agreement with a role for adaptive immunity in generating the protective response seen 
earlier, RAG2-/- animals receiving either Listeria-OVA or PBS had no difference in 
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overall median survival (Fig 3-3). These data demonstrate that neither of these vaccines 
have potent oncolytic function, and instead function through the generation of an 
adaptive immune response to produce anti-tumor effects. 
Protective Immunity Generated by Listeria-OVA Vaccines is Dependent on CD8+ T Cells 
 RAG2-/- animals are missing several populations of adaptive immune cells, 
including B cells, CD4+ T cells, CD8+ T cells, and NKT cells. To test if a CD8+ T cell 
response was required for anti-tumor immunity, we utilized a depleting antibody schedule 
to remove only CD8+ T cells from the host animals, and repeated our vaccination studies 
(Fig 3-4a). The antibody depletion regimen was very effective, resulting in a decreased of 
>99% of normal, circulating CD8+ T cells after as little as two doses (Fig 3-4b,c). As can 
be seen in Figure 3-4d, depletion of CD8+ T cells from the host mice abrogates the 
previous protection seen with Listeria-OVA vaccination. Furthermore, when CD8+ T 
cells are depleted, Listeria-OVA and Vaccinia-OVA vaccinations provided similar 
protection, suggesting that the CD8+ T cell response generated by these two vaccines was 
one of the key cellular differences. Interestingly, despite generating an OVA specific 
CD8+ T cell response (Fig5-6a), Vaccinia-OVA vaccination was relatively unaffected by 
CD8+ T cell depletion. Hence, the protection being generated by Vaccinia-OVA is 
predominantly not CD8+ T cell dependent, and must be generating an anti-tumor adaptive 
immune response with some other population, likely CD4+ T cells.   
Summary 
 In summary, both Listeria and Vaccinia vaccination platforms resulted in anti-
tumor immune responses, in an adaptive immunity based manner. This anti-tumor 
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immunity was generated against a variety of model tumors, and Listeria-OVA provided 
superior anti-tumor responses across all models. Interestingly, in the absence of an 
adaptive immune response, Vaccinia-OVA vaccination actually decreased overall 
survival, while Listeria-OVA simply offered no additional benefit. This finding shows 
some of the dangers of the use of live-attenuated vaccinations in certain populations, 
specifically those who are immunocompromised. Virulence of strains utilized as live-
attenuated vaccines must be closely monitored, as many cancer patients have immune 
systems that are weakened by their chronic disease. Furthermore, while depletion of 
CD8+ T cells resulted in a loss of the protective immunity generated by Listeria-OVA 
vaccination, Vaccinia-OVA protection was similar with and without depletion, 
suggesting that despite the generation of OVA specific CD8+ T cells, these cells were 
non-functional, unlike those generated by Listeria-OVA vaccination. These data indicate 
that these two vaccine vectors program very different CD8+ T cell responses, and that the 







Figure 3-1: Listeria Monocytogenes Vaccination Produces Superior Anti-Tumor 
Effect in Subcutaneous Cancer Models 
Host mice were injected subcutaneously with 1-1.5x105 A) B16-OVA or B) EL4-OVA 
on the right flank. Three days later, mice were vaccinated with either PBS, 107 cfu of 
Listeria-OVA, or 106 pfu of Vaccinia-OVA via intravenous injection and tumor volume 
was measured over time. Data shown are representative of greater than 3 independent 


















Figure 3-2: Listeria Monocytogenes Vaccination Produces Superior Anti-Tumor 
Effect in Metastatic Cancer Models 
Host mice were injected intravenously with 1-1.5x105 B16-OVA. Three days later, mice 
were vaccinated with either PBS, 107 cfu of Listeria-OVA, or 106 pfu of Vaccinia-OVA 
via intravenous injection. A) Survival curves of mice receiving the individual 
vaccinations. B) On day 18, lungs were harvested from vaccinated animals, fixed 
overnight, and photographed. C) Number of micro-metastatic B16-OVA lesions counted. 













Figure 3-3: The Protective Immunity Generated by Listeria Monocytogenes 
Vaccination is Dependent Upon an Adaptive Immune Response 
RAG2-/- host mice were injected intravenously with 1-1.5x105 B16-OVA. Three days 
later, mice were vaccinated with either PBS, 107 cfu of Listeria-OVA, or 106 pfu of 
Vaccinia-OVA via intravenous injection and monitored for survival over time. Data 
shown are representative of 2 independent experiments, with n=5 mice per group. 
  






























Figure 3-4: The Protective Immunity Generated by Listeria Monocytogenes 
Vaccination is Dependent Upon CD8+ T Cells 
Prior to implanting tumor, mice were depleted of CD8+ T cells by repeated intraperitonial 
administration of 200µg of 2.43 depleting antibody. On day zero, host mice were injected 
intravenously with 1-1.5x105 B16-OVA. Three days later, mice were vaccinated with 
either PBS, 107 cfu of Listeria-OVA, or 106 pfu of Vaccinia-OVA via intravenous 
injection. A) CD8+ T cell depletion regimen and experimental design B) Flow cytometric 
analysis and C) quantification of peripheral blood CD8+ T cells on day -1. D) Survival of 
animals over time following tumor implantation and vaccination.  Data shown are 












LISTERIA MONOCYTOGENES BASED VACCINES RESULT IN INCREASED IN 
POLYFUNCTIONAL CYTOKINE PRODUCTION AND A TRANSCRIPTION 





 While early studies in Immunology focused on the production of certain or single 
effector cytokines, more recent work has begun to identify an important role for the 
production of multiple cytokines. In several studies, combinatorial checkpoint protein 
blockade allowed for recovery of not only IFNγ, but also of TNFα and IL-243,45,147. 
Furthermore, the generation of polyfunctional cytokine producing CD8+ T cells has been 
linked to anti-tumor immunity. Along the same lines, early work has determined a role 
for the expression of single transcription factors in T cell activation and function, but 
more research will need to be done to examine the effects of expressing combinations of 
transcription factors. Finally, several different lines of research, including our own, has 
suggested that the initial programming of CD8+ T cells is vitally important in determining 
their end functionality148–150. For example, blockade of PD-1 during the initial priming 
response generates CD8+ T cells with increased cytolytic potential, while blockade one 
day after vaccinations offers no benefit149. In our previous studies, we were using the 
host’s endogenous response to examine the potential benefit of these two vaccines. 
However, while this model is the most like a clinical model, the generation of an 
endogenous response only allows for immunological examination later in the priming 
response, once the CD8+ T cell population has expanded to detectable levels. As such, we 
decided to investigate the cytokine and transcription factor profile in an adoptive transfer 





Chapter Specific Materials and Methods 
Adoptive Transfer and Vaccination Experiments 
 To study the effects of these vaccines on early CD8+ T cell programming and 
development, adoptive transfer studies were undertaken. Briefly, CD8+ T cells were 
harvested from the spleen and peripheral lymph nodes of 12-16 week old female OT-1 
Rag2-/- animals (or Clone 4 Thy1.1+ animals in certain experiments), passed through a 
100µM cell filter, and RBCs were lysed in ACK buffer (Life Technologies, Grand Island, 
New York) before the remaining cells were quenched with MACS buffer and counted. 
Following the generation of a single cell suspension, CD8+ T cells were isolated 
according to manufacturer’s protocol utilizing a Miltenyi CD8+ T cell positive isolation 
kit (Miltenyi, San Diego, CA). Cells were then labeled with 5µM Carboxyfluorescein 
Succinimidyl Ester(CFSE). For CFSE labeling, 5mM CFSE (Life Technologies, Grand 
Island, New York) was generated by dilution of lyophilized CFSE in DMSO, and a 5µM 
generated for staining by dilution in PBS. Cells were washed in cold PBS before being 
resuspended in a 5µM CSFE solution at a concentration of 2.5x107 cells/mL. This 
staining solution was incubated for 8 minutes shaking at 800RPM at 37°C, before the 
reaction was quenched with 10X volume of ice cold, complete RPMI for 3 minutes. Cells 
were washed twice with ice cold PBS before being recounted, and resuspended for 
adoptive transfer. For adoptive transfer studies, 1-2x106 CD8+ T cells were admixed with 
their vaccination (PBS, 106 pfu Vaccinia, 107 cfu Listeria), for a final injection volume of 
200 µL of cells + vaccine in PBS. Admixed cell and vaccine combos were then 




CD8+ T cells Responding to Listeria-OVA Vaccination Display Increased   
Polyfunctional Cytokine Production 
 To test the hypothesis that Listeria-OVA based vaccinations result in increased 
polyfunctional cytokine production in specifically activated  CD8+ T cells, we adoptively 
transferred congenically marked, CFSE labeled OVA specific CD8+ T cells, named OT-
1s, into host mice along with vaccinations of PBS, Listeria-OVA, or Vaccinia-OVA. In 
the interest of having a negative control for activation, we included a group of host mice 
that express OVA as a self-protein under the β-actin promoter. These mice, named CAG-
OVA, provide a system where OT-1s recognize their cognate antigen in a non-activating 
condition, and will therefore be tolerized.  As expected, adoptively transferred OT-1s in 
mice with no vaccine and no endogenous OVA expression did not divide, and produced 
no cytokines upon restimulation (Fig 4-1a,b). In contrast, OT-1s exposed to the tolerizing 
conditions of the CAG-OVA host did divide, but produced very few cytokines. Vaccinia-
OVA vaccinated OT-1s produced all of the cytokines examined, including IFNγ, TNFα, 
IL-2, and Granzyme B. However, Listeria-OVA primed OT-1s produced the largest 
populations of cytokine producing cells for all the cytokines examined, with the notable 
exception of IL-2 (Fig4-1a, b). Interestingly, Vaccinia-OVA primed OT-1s produced the 
most IL-2+ cells, suggesting again that they may be programmed differently than OT-1s 
responding to Listeria-OVA. However, while there was a statistically significant 
increase, the percentage of OT-1s producing effector cytokines in response to Listeria 
was only about 10% higher than those responding to Vaccinia. Therefore, we found it 
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unlikely that this small, but statistically significant increase in cytokine production was 
the driving force behind the increased anti-tumor effect observed earlier. 
To examine the ability of the vaccinated OT-1s to produce multiple cytokines, we 
quantified all possible combinations of the four individual cytokines examined. Perhaps 
not surprisingly, we found that Listeria-OVA vaccinated OT-1s had the greatest 
percentage of cells producing two or more cytokines (Fig 4-2a,b). Furthermore, the 
increase in polyfunctional CD8+ T cell responses correlated with decreased percentages 
of OT-1s making none of the examined cytokines when compared to Vaccinia-OVA 
primed OT-1s (Fig 4-2). Together, these data show that as early as three days post 
vaccination, the majority of the cells responding to both vaccines produce multiple 
cytokines. Yet, Vaccinia-OVA and Listeria-OVA based vaccines result in different 
cytokine profiles within the responding CD8+ T cells, with Listeria-OVA vaccinated 
CD8+ T cells producing larger populations of cytokine expressing cells, as well as 
increased populations expressing multiple cytokines. As polyfunctional CD8+ T cells 
have been shown to have increased anti-tumor efficacy, the differences in the cytokine 
profile generated in response to these two vaccines could potentially explain some of the 
differences in anti-tumor immunity being generated. 
CD8+ T cells Responding to Listeria-OVA Vaccination Display An                        
Activation Focused Transcription Factor Profile 
 Given that we saw significant differences in cytokine production, we next tested 
the hypothesis that Listeria-OVA and Vaccinia-OVA generate different transcription 
factor profiles in responding CD8+ T cells. Similar to the previous experiments, we 
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adoptively transferred OT-1s into the previous four conditions for three days. As seen 
before, in the absence of antigen, OT-1s did not divide and did not up regulate any of the 
transcription factors investigated. Interestingly, adoptive transfer of OT-1s into CAG-
OVA hosts resulted in these cells dividing, as seen before, but they did not up regulate 
transcription factors previously correlated with CD8+ T cell activation, namely Tbet and 
Eomesedermin. However, they did up regulate a transcription factor originally identified 
as a tolerogenic CD4+ T cell transcription factor, named Egr2 (Fig 4-3a,b). The CD4+ T 
cell literature151,152, along with the expression of Egr2 in the  OT-1s transferred into a 
CAG-OVA hosts, suggests that this factor is also associated with CD8+ T cell tolerance, 
and may work against CD8+ T cell activation. Surprisingly, while Vaccinia-OVA 
vaccination did result in up regulation of the activating transcription factors Tbet and 
Eomesedermin, it also resulted in the up regulation of Egr2, creating a mixed 
transcription factor profile. In contrast, Listeria-OVA based vaccination caused only 
unregulation of the activating factors, without up regulation of Egr2 (Fig 4-3a,b).  
 As before, we wanted to examine the profile of combined expression, as each 
transcription factor likely has input into the eventual functionality of the CD8+ T cells. 
Interestingly, when assessing the percent of the overall CD8+ OT-I T cell population 
expressing any of the combinations of transcription factors, CAG-OVA stimulated OT-1s 
expressed predominantly Egr2 alone. Vaccinia-OVA vaccinated OT-1s expressed 
predominantly combinations of Tbet and Eomesedermin, but about 15% of the population 
did express combinations of Tbet and Eomesedermin along with Egr2. About 5% of OT-
1s responding to Vaccinia-OVA vaccination even expressed Egr2 alone (Fig 4-4). This is 
significantly different than Listeria-OVA vaccinated OT-1s, where only about 5% of the 
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cells expressed Egr2 in any form, and about 85% of the cells expressed only 
combinations of Tbet and Eomesedermin. Taken together, Listeria-OVA vaccinations 
seem to drive a more activating CD8+ T cell transcription factor profile, and do not drive 
expression of tolerogenic factors such as Egr2. In contrast, while Vaccinia-OVA primed 
CD8+ are activated, they may be sub-optimally activated as they up regulate expression 
of the tolerogenic transcription factor Egr2. 
Summary 
 While the expression of single effector proteins has resulted in increased 
understanding of the roles each of those proteins play in an immune response, current 
research has begun to unravel the meaning behind combinations of effector cytokines, or 
combinations of transcription factors. In these data, we demonstrate that Listeria-OVA 
vaccines generate increases both in the percentage of CD8+ T cells expressing individual 
effector cytokines, as well as those expressing of multiple cytokines, with the notable 
exception of IL-2. Furthermore, Vaccinia-OVA vaccination did generate expression of 
classical CD8+ T cell activation transcription factors, but did not drive expression of these 
activation markers exclusively. Populations of cells expressing the tolerogenic 
transcription factor Egr2 were seen, unlike during the response to Listeria-OVA. The 
resulting transcription factor phenotype is likely the driving force behind the differences 
in cytokine production, as Tbet and Eomesedermin have been shown to play a prominent 
role in the production of effector cytokines during CD8+ T cell activation153,154. 
Interestingly, in Tbet knockout CD8+ T cells, increases in IL-2 production have been 
seen, correlating with our data on Listeria and Vaccinia vaccinations154. Furthermore, 
Egr2 knockout CD4 T cells produce more IFNγ when stimulated both in vitro and in 
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vivo155, suggesting that the mixed expression of Tbet, Eomesedermin, and Egr2 in CD8+ 
T cells responding to Vaccinia may correlate with the lower percentages of cytokine 
producing cells. However, these differences, while statistically significant, biologically 
seem small in scale, and so are unlikely, in our opinion, to be the driving molecular 
difference between the functionality of the CD8+ T cell response generated by these two 
vaccines. Nevertheless, these data do support the hypothesis that these vaccines program 
a fundamentally different CD8+ T cell response, and that this difference is clear as early 
























Figure 4-1: Listeria Monocytogenes Vaccinations Result in Larger Populations of 
Effector Cytokine Producing Cells 
CFSE labeled OT-1s were admixed with their vaccine and then adoptively transferred 
into recipient host mice, either congenically marked CD45.1+ wildtype or CAG-OVA 
mice. On day three, spleens were harvested, and splenocytes were restimulated with 
OVA peptide in the presence of protein transport inhibitor for 5 hours prior to 
intracellular staining for cytokine expression. A) Cells were gated on CFSE expression as 
well as CD8 and CD45.2, and are depicted as A) Flow cytometry dot plots and B) 
quantified graphs of the percent of each population expressing a given cytokine. Data 





































Figure 4-2: Listeria Monocytogenes Vaccinations Result in Larger Populations of 
Polyfunctional CD8+ T Cells 
CFSE labeled OT-1s were admixed with their vaccine and then adoptively transferred 
into the recipient host mice as previously. A) Cells were gated on CFSE expression as 
well as CD8 and CD45.2, before expression of all possible combinations of cytokines 
were examined as A) pie charts and B) quantifiable bar charts. Data shown are 






















Figure 4-3: Listeria Monocytogenes Vaccinations Result in Increased Populations of 
Cells Expressing Activating Transcription Factors 
CFSE labeled OT-1s were admixed with their vaccine and then adoptively transferred 
into recipient host mice, either congenically marked CD45.1+ wildtype or CAG-OVA 
mice. On day three, spleens were harvested, and splenocytes stained intracellularly for 
transcription factor expression. A) Cells were gated on CFSE expression as well as CD8 
and CD45.2, before being examined as for expression of individual transcription factors 
and B) quantified. Data shown are representative of greater than 3 independent 






Figure 4-4: Listeria Monocytogenes Based Vaccinations Result in a More Activation 
Focused Transcription Factor Profile 
CFSE labeled OT-1s were admixed with their vaccine and then adoptively transferred 
into the same recipient host mice as previously described. Cells were gated on CFSE 
expression as well as CD8 and CD45.2, before being examined as for expression of all 
possible combinations of transcription factors. Data shown are representative of greater 













LISTERIA MONOCYTOGENES BASED VACCINES ALLOW FOR CD8+ T CELL 





 As discussed above, checkpoint proteins play an important role in maintaining 
tolerance to self-proteins as well as controlling the magnitude of the immune response 
being generated. Previous studies in our lab have demonstrated that the addition of in 
vivo PD-1149 or LAG-344 blockade during activation in the settings of self-tolerance or 
infection results in increased magnitude of T cell expansion as well as increased cytokine 
production. Blockade of PD-1 during the course of an acute infection plays a role in the 
eventual development of memory function, though whether it positively or negatively 
regulates the development of memory T cells has yet to be fully understood. In one study, 
blockade of PD-1 during the course of Vaccinia infection resulted in increased acute and 
memory responses, as well as increased expression of central memory markers like 
CCR7, as well as increased IL-2 production156. Additionally, in another study, PD-1 
knockout animals were able to survive a dose of the fungus Histoplasma Capsulatum that 
was 10x the normal lethal dose, suggesting that PD-1 expression negatively regulates the 
development of host immunity during acute infections157. Likewise, blockade of LAG-3 
has been found to expand T cell response to a variety of stimuli27. Additionally, 
combinatorial blockade of multiple checkpoint proteins has been found to generate potent 
responses to typically chronic infection33,147,158. However, the fact that blockade of 
checkpoint proteins assists in the generation of an acute response to vaccination is 
predicated on the expression of these checkpoints during the activation of the adaptive 
immune response. Indeed, checkpoint protein expression has long been a hallmark of 
CD4+ and CD8+ T cell activation. However, the exact expression of certain checkpoints 
in response to individual vaccines has not been fully explored, and future research is 
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necessary to determine if certain combinations of checkpoint proteins are expressed 
preferentially in the acute settings of vaccination. 
Chapter Specific Materials and Methods 
Tetramer Staining and Memory Rechallenge Experiments 
 To stain tetramer-specific cells, we modified the previous extracellular staining 
protocol to include a new initial step. For staining tetramer positive cells in the peripheral 
blood, approximately 100 µL of blood was collected into 2% sodium citrate in complete 
RPMI from a small incision in the tail vein daily. Following collection of the blood, 
styptic powder (Petco, Baltimore, MD) was used to stop the tail from bleeding. RBCs 
were lysed for 5 minutes in 200 µL of ACK buffer, before being washed twice with 
200µL MACs buffer. For some studies, single cell suspensions from the spleen or lymph 
nodes were stained as well. To stain tetramer, once a single cell suspension had been 
obtained, cells were incubated for 25 minutes at room temperature in the dark with OVA 
tetramer reagent (Beckman Coulter, Brea, CA) resuspended in MACs buffer, at a 
concentration of about 5x106 per 50 µL. Cells were washed once with 200 µL MACS 
buffer, before extracellular staining was done as previously stated.  
 For memory experiments, host mice were primed on Day 0 with either PBS, 106 
pfu Vaccinia-OVA, or 107 cfu Listeria-OVA, all by tail vein injection. On Day 40, mice 
were rechallenged subcutaneously on Day 40 with an emulsion of Addavax (Invivogen, 
San Diego, CA) containing 10 µg of whole OVA protein. For a control for tetramer 
staining, some mice received 107 cfu Listeria-OVA via tail vein injection on Day 40. On 
Day 45, spleens and draining lymph nodes were harvested to examine the effects of a 
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Listeria or Vaccinia based prime on subsequent recall responses as well as PD-1 and 
LAG-3 expression. 
Results 
Listeria Based Vaccinations Drive CD8+T Cell Divisions Without                                  
the Up Regulation of PD-1 or LAG-3 
 The role of checkpoint proteins in the development of an immune response has 
been documented in a variety of models. Therefore, we investigated whether our 
vaccinations caused different expression of checkpoint proteins during the early stages of 
CD8+ T cell activation. Similar to previous experiments, we chose to investigate this 
question through the use of an adoptive transfer model. As anticipated, adoptive transfer 
of OT-1s into a tolerizing host (CAG-OVA) resulted in robust up regulation of both PD-1 
and LAG-3. As has been seen in other models CD8+ T cell activation, Vaccinia-OVA 
vaccine caused intermediate up regulation of both PD-1 and LAG-3 on the adoptively 
transferred OT-1s, as well as some expression of 2B4. Surprisingly, however, Listeria-
OVA primed OT-1s showed no up regulation of PD-1, and minimal expression of LAG-3 
(Fig 5-1a). This was confirmed by adoptively transferring PD-1-/- OT-1s into the same 
host groups, and comparing the expression of PD-1 on wildtype OT-1s to that of PD-1-/- 
OT-1s when both when given Listeria-OVA as a vaccination (Fig 5-2a,b). To analyze 
this phenotype deeper, we examined the mean fluorescence intensity (MFI) of PD-1 and 
LAG-3 on OT-1s as a function of division for our two vaccinations. The expression of 
PD-1 and LAG-3 on OT-1s primed against Vaccinia-OVA matched the expression 
profile reported in other vaccine studies, namely peaking on the first division, and 
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decreasing as the cells divided further. However, the expression of PD-1 on OT-1s 
responding to Listeria-OVA never increased, and in fact, stayed relatively stable despite 
multiple divisions (Fig 5-1b). LAG-3 expression also did not have the expected early 
peak, instead staying well below the MFI on Vaccinia-OVA vaccinated OT-1s. 
Interestingly, the expression of CD160 was also significantly different when examined as 
MFI, though the biological significance of this is currently unclear.  
Listeria Based Vaccinations Drive CD8+T Cell Activation Without                         
Combinatorial Expression of Checkpoint Proteins 
 Having observed such a striking phenotype when examining individual 
checkpoint proteins, we proceeded to analyze the combinatorial expression of these 
molecules. As would be expected from the individual expression data, the greatest 
combinatorial expression of checkpoints was seen on the OT-1s adoptively transferred 
into CAG-OVA hosts. Vaccinia-OVA vaccinated OT-1s also showed expression of 
multiple checkpoints, with approximately 25% of the population expressing 2 or more of 
the indicated checkpoints. However, OT-1s from Listeria-OVA vaccinated mice had 75% 
of the population expressing none of the examined checkpoints, and only about 4% 
expressing 2 or more checkpoints (Fig 5-3a).  
 As different combinations of checkpoint proteins have been reported in the 
literature, we also wanted to analyze specifically which combinations of checkpoints 
were being expressed. Interestingly, when examining the combinations seen on the OT-1s 
transferred into CAG-OVA hosts, the dominant populations of cells expressed PD-1 
alone (~60%), followed by PD-1 and LAG-3 (~25%), suggesting that PD-1 and LAG-3 
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play prominent roles in early tolerance mechanisms. On Vaccinia-OVA primed OT-1s, 
combinations of PD-1 and LAG-3 were prevalent (~40%), while approximately 40% of 
the cells expressed none of the checkpoint proteins investigated (Fig 5-3b). Surprisingly, 
a population of cells expressing LAG-3 alone also existed, though this may be a function 
of vaccinations being generally activating settings, while most co-expression studies to 
date have been pursued in tolerizing conditions. Finally, in OT-1s being primed by 
Listeria-OVA, the vast majority of cells (~75%) expressed none of the checkpoint 
proteins, followed by expression of 2B4 alone. Together, these data show that Listeria-
OVA vaccines have an extremely unique phenotype and allow for early CD8+ T cell 
activation without expression of multiple checkpoint proteins. Furthermore, to the best of 
our knowledge, these data are the first to demonstrate that checkpoint protein up 
regulation may not be a requirement for CD8+ T cell activation, but instead that CD8+ T 
cells up regulate certain checkpoint proteins in response to individual pathogens.  
CD8+T Cell Activation Without PD-1 Up Regulation is a Function                                     
of the ActA Attenuation in the Listeria Vector 
 As Listeria Monocytogenes is a relatively well studied pathogen in the field of 
immunology, we wanted to explore why this CD8+ T cell phenotype had not been 
observed previously. The Listeria vaccine being utilized in these studies was attenuated 
through the genetic deletion of two genes; Internalin B (IntB) and Actin Assembly 
Inducing Protein A (ActA)136. With these genes knocked out, the Listeria vector tends to 
end up specifically in phagocytic cells of the immune system (IntB), and cannot escape 
the originally infected cell through the use of actin tails (ActA). Therefore, we wanted to 
test the hypothesis that the genetic attenuations of our strain of Listeria created the unique 
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CD8+ T cell phenotype we had observed. To do this, we adoptively transferred CFSE 
labeled OT-1s into congenically marked host mice with either PBS, WT Listeria-OVA, 
IntB -/- Listeria-OVA, ActA -/- Listeria-OVA, or ActA -/- IntB -/- Listeria-OVA (the strain 
we used in the previous experiments). We also adoptively transferred CFSE labeled OT-
1s into CAG-OVA host mice as a positive control for PD-1 up regulation. Interestingly, 
WT Listeria-OVA vaccination resulted in the adoptively transferred OT-1s up regulating 
PD-1 during their activation (Fig 5-4). This phenotype was mirrored when IntB -/- 
Listeria-OVA was used as the vaccine, suggesting that the loss of IntB is not what is 
causing this CD8+ T cell phenotype. However, ActA -/- Listeria-OVA primed OT-1s were 
an exact phenocopy of the fully attenuated strain used in the previous experiments, 
suggesting that the deletion of ActA from the Listeria genome resulted in the activation 
of CD8+ T cells without up regulation of PD-1.  
CD8+T Cell Activation Without PD-1 Up Regulation is Not a                                         
Function of the OT-I Adoptive Transfer Model  
 Since previous reports have always seen PD-1 up regulation as a function of 
CD8+ T cell activation, we wanted to further explore whether the unique phenotype 
generated by Listeria based vaccination was a function of the model system being 
utilized. To test this, we replicated our previous adoptive transfer studies utilizing a 
different CD8+ T cell transgenic donor mouse, Clone 4, which produces CD8+ T cells 
specific for the influenza protein hemaglutinin (HA) on a B10.D2 background (H-2kd). 
Similar to the previous experiments, we adoptively transferred these HA specific CD8+ T 
cells into new hosts along with PBS, Vaccinia-HA, or Listeria-HA. We also adoptively 
transferred CD8+ Clone 4 T cells into a mouse model expressing HA as a self-protein, 
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named C3-HAlo, as a model of non-inflammatory activation as well as positive control 
for PD-1 expression. When we examined PD-1 and LAG-3 expression on the adoptively 
transferred cells after three days, we found the same phenotype we discovered when 
using the OT-1:C57/B6 system. As before, Clone 4s transferred into C3-HAlo hosts 
divided in response to their target antigen, but also expressed high levels of the 
checkpoint proteins PD-1 and LAG-3(Fig 5-5a). In mice that received Vaccinia-HA, PD-
1 and LAG-3 expression on the dividing Clone 4s was intermediate, while Clone 4s 
primed against Listeria-HA expressed negligible levels of PD-1 and LAG-3. 
Additionally, as seen in the C57/B6 system, PD-1 and LAG-3 expression as a function of 
division was minor in the Listeria-HA vaccinated mice (Fig 5-5b). Together, these data 
show that activation of CD8+ T cells without PD-1 expression by Listeria based vaccines 
is not a function of the model system being utilized, but is instead of function of the 
vaccine vector being used. 
Listeria Monocytogenes Based Vaccines Result in Significantly Decreased PD-1 and 
LAG-3 Expression on Endogenously Generated, Vaccine Specific CD8+ T cells 
 While our adoptive transfer system allows for examination of the earliest events 
of CD8+ T cell activation, in our tumor treatment models, we did not utilize adoptive 
transfer therapy. Therefore, we examined the expression of PD-1 and LAG-3 on OVA 
tetramer+ CD8+ T cells in the peripheral blood of host animals following vaccination. As 
we saw previously, Listeria-OVA vaccination resulted in a greater expansion of tetramer+ 
CD8+ T cells (Fig 5-6a). Surprisingly, even during the generation of an endogenous CD8+ 
T cell response, Listeria based vaccination resulted in significantly decreased expression 
of both PD-1 and LAG-3, though we did see some expression of these proteins during the 
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generation of the endogenous response (Fig 5-6b,c). Importantly, the largest difference 
between the CD8+ T cell responses generated by the two vaccine vectors was the 
expression of PD-1 with or without LAG-3. Together, these data show that Listeria based 
vaccines result in significantly decreased PD-1 and LAG-3 expression in both adoptive 
transfer models, as well as in the generation of an endogenous CD8+ T cell response.  
Listeria Monocytogenes Vaccination Does Not Prevent                                                    
PD-1 Expression During Memory Responses 
 Since expression of PD-1 has previously been correlated with CD8+ T cell 
activation during vaccinations, we wanted to see if our Listeria primed CD8+ T cells were 
capable of PD-1 expression during a memory response, or if PD-1 expression on these 
CD8+ T cells had been permanently altered in some way by this vaccination. To test the 
hypothesis that PD-1 expression was only affected during the initial exposure to Listeria 
vaccination, mice were vaccinated with PBS, Vaccinia-OVA, or Listeria-OVA. Forty 
days after the initial vaccines, mice were rechallenged with whole OVA protein mixed 
with Addavax adjuvant subcutaneously. Interestingly, unlike previous reports, we found 
no deficit in the second expansion of tetramer positive cells in the draining lymph of mice 
receiving the Listeria-OVA priming vaccine, and in fact, found a larger population of 
tetramer positive cells than with in mice primed with Vaccinia-OVA (Fig 5-7a). 
Additionally, unlike during the primary response to these vaccines, we found no 
difference in either CD8+ T cell expansion or checkpoint protein expression between our 
two vaccines (Fig. 5-7b,c). Therefore, PD-1 and LAG-3 expression is modulated during 
the priming response to Listeria based vaccination, but is not repressed permanently 
throughout the life of these CD8+ T cells. 
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PD-1 Expression During Vaccination is One of the Molecular                                           
Causes of Differing Anti-Tumor Immunity 
 Due to the striking PD-1 expression differences between OT-1s responding to 
Vaccinia-OVA and those responding to Listeria-OVA, we wanted to test whether this 
difference resulted in the differences in anti-tumor immunity generated by these two 
vaccines. To test this hypothesis, we utilized PD-1-/- host mice, such that no cells could 
up regulate PD-1, with or without vaccination. We then repeated our prior intravenous 
tumor vaccination study in these new host animals, examining survival as a readout of 
anti-tumor immunity. Strikingly, despite the differences in anti-tumor immunity 
generated by these vaccines in wildtype animals, PD-1-/- host animals showed equal 
survival benefit with Vaccinia-OVA or Listeria-OVA vaccination (Fig 5-8), suggesting 
that the differences we observed in PD-1 expression were biologically significant, and 
potentially the main molecular difference creating the observed functional difference.  
Summary 
The role of checkpoint proteins in early T cell activation has just begun to be 
understood. While PD-1 expression has sometimes been used as a readout for CD8+ T 
cell activation in vaccination settings, both our lab as well as others have shown the 
therapeutic effects of blocking PD-1 or LAG-3 during the early priming response, 
suggesting that these proteins are still signaling during activation. Checkpoint blockade 
during the priming phase often results in increased initial expansion, increased cytokine 
production, and higher levels of functional cytolytic activity. Perhaps not surprisingly, the 
molecular advantages we observed phenotypically when using a Listeria vaccination 
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mimic those seen during checkpoint blockade studies, further suggesting that checkpoint 
protein expression is one of the defining differences between these two vaccinations. 
Here, we have shown that checkpoint expression is not a pre-requisite for CD8+ T cell 
activation, and in fact, some vaccine vectors may modulate expression of individual 
checkpoint proteins differently. Furthermore, modulation of PD-1 expression is not a 
function of the adoptive transfer model, or the target antigen and mouse background. This 
phenotype is dependent specifically on the genetic deletion of ActA from the Listeria 
vaccine, demonstrating that the key to this phenotype is likely the Listeria entering the 
cytoplasm of an APC and staying there. Finally, by deleting PD-1 and preventing either 
vaccine from driving PD-1 expression, we were able to extend the survival time of 
animals receiving Vaccinia-OVA, such that these two vaccines had similar anti-tumor 
effects. Thus, the difference in PD-1 expression during response to these two vaccines is 
likely one of the major molecular differences that explains their difference in anti-tumor 






















Figure 5-1: Listeria Monocytogenes Vaccinations Drive CD8+ T Cell Divisions 
Without Up Regulation of the Checkpoint Proteins PD-1 and LAG-3 
CFSE labeled OT-1s were admixed with their vaccine and then adoptively transferred 
into recipient host mice, either congenically marked CD45.1+ wildtype or CAG-OVA 
mice. On day three, spleens were harvested, and splenocytes stained intracellularly for 
transcription factor expression. A) Cells were gated on CFSE expression as well as CD8 
and CD45.2, before being examined as for expression of individual checkpoint proteins 
and B) quantified. Data shown are representative of greater than 3 independent 






























Figure 5-2: Listeria Monocytogenes Vaccinations Result in CD8+ T Cell Activation 
Without PD-1 Expression 
CFSE labeled wildtype or PD-1-/- OT-1s were admixed with their vaccine and then 
adoptively transferred into recipient host mice, either congenically marked CD45.1+ 
wildtype or CAG-OVA mice. On day three, spleens were harvested, and splenocytes 
stained for PD-1 expression. A) Dot plots of PD-1 expression on donor OT-I CD8+ T 
cells and B) quantification of PD-1 expression. Data shown are representative of at least 










































Figure 5-3: Listeria Monocytogenes Vaccinations Drive CD8+ T Cells To Divide 
Without Combinatorial Expression of Checkpoint Proteins 
CFSE labeled OT-1s were admixed with their vaccine and then adoptively transferred 
into the same host mice as previous experiments. On day three, spleens were harvested, 
and splenocytes stained for checkpoint protein expression. Cells were gated on CFSE 
expression as well as CD8 and CD45.2, before being examined as for expression of A) 
multiple checkpoint proteins or B) patterns of checkpoint proteins. Data shown are 

























Figure 5-4: Activation of CD8+ T Cells Without PD-1 Expression is Dependent on 
the ActA Deletion in the Live, Attenuated Listeria Monocytogenes Vector 
CFSE labeled OT-1s were admixed with live-attenuated strains of Listeria 
Monocytogenes with different genetic attenuations, before being adoptively transferred 
into recipient host mice, either congenically marked CD45.1+ wildtype or CAG-OVA 
mice. On day three, spleens were harvested, and splenocytes stained for checkpoint 
protein expression. Cells were gated on CFSE expression as well as CD8 and CD45.2, 
before being examined as for expression of individual checkpoint proteins. Data shown 
























Figure 5-5: Activation Without Expression of Checkpoint Proteins Is Not A 
Function of the OT-I Adoptive Transfer Model 
CFSE labeled Clone 4s were admixed with their vaccine and then adoptively transferred 
into recipient host mice, either congenically marked Thy1.2+ wildtype or C3-HA mice. 
On day three, spleens were harvested, and splenocytes stained intracellularly for 
transcription factor expression. A) Cells were gated on CFSE expression as well as CD8 
and Thy1.1, before being examined as for expression of individual checkpoint proteins 
and B) MFI of individual checkpoints as a function of division. Data shown are 




































Figure 5-6: Endogenous Antigen Specific CD8+ T cells Generated in Response to 
Listeria Vaccination Have Significantly Attenuated PD-1 and LAG-3 Co-Expression 
C57/B6 mice were vaccinated on Day 0 with either PBS, 106 pfu Vaccinia-OVA, or 107 
cfu Listeria-OVA, and peripheral blood was collected daily and stained for A) OVA 
tetramer specificity, as well as B) PD-1 and LAG-3 expression on Day 5. One C57/B6 
OT-1 mouse was bled daily as a positive control for tetramer staining.  C) Quantification 
of checkpoint co-expression. Data shown are representative of at least 2 independent 
























Figure 5-7: Listeria Vaccinations Do Not Control Future PD-1 Expression During 
Recall Responses 
C57/B6 mice were primed with either PBS, Vaccinia-OVA, or Listeria-OVA. On Day 
40, mice were rechallenged subcutaneously with whole OVA protein mixed with 
Addavax adjuvant, and spleens and draining lymph nodes were harvested 5 days later and 
stained for A) tetramer positivity, as well as B-C) PD-1 and LAG-3 expression. 
Unvaccinated mice were used as a negative control for tetramer staining, while some 
mice receiving LM-OVA on day 40 as a positive control for tetramer staining.  Data 






Figure 5-8  
  
Figure 5-8: PD-1 Expression During Vaccination is One of the Major Molecular 
Drivers of Differences in Functional Anti-Tumor Immunity 
PD-1-/- host mice were injected intravenously with 1-1.5x105 B16-OVA. Three days later, 
mice were vaccinated with either PBS, Listeria-OVA, Vaccinia-OVA via intravenous 
injection and monitored for survival over time. Data shown are representative of at least 2 
independent experiments, with n=3-5 mice per group. Statistics compare the overall 
















CD8+ T CELL ACTIVATION WITHOUT PD-1 EXPRESSION IS INDEPENDENT 





 Several groups have begun to characterize the different pathways stimulated by 
Listeria Monocytogenes. In these studies, it has been found that heat killed Listeria 
Monocytogenes based vectors stimulate antigen presenting cells differently than 
metabolically active Listeria130,159. Indeed, Listeria infections have been reported to be 
sensed both by extracellular121 as well as intracellular122–125 pathogen associated pattern 
receptors. However, the final result of many of these sensors, and the only known 
pathway required for the production of IFNβ, involves TBK1 and IRF3107. Yet, in vivo, 
there is likely some overlap between the initial set of sensors registering the infection and 
the final signaling pathway.  MyD88 is a crucial adaptor protein for many of the innate 
pattern recognition receptors, including many of the Toll-like receptors160. Studies have 
shown both MyD88 dependent121 and independent mechanisms of responding to Listeria 
Monocytogenes infection. Additional recent work has identified the potential for the 
STING and RIGI pathways in the recognition of Listeria by host cells122–124. In this 
chapter, we examined many of the hallmarks of Listeria infection that we thought may be 
capable of the unique CD8+ T cell activation phenotype that is seen when using this live-
attenuated strain of Listeria Monocytogenes. 
Chapter Specific Materials and Methods 
In Vitro Stimulation With IFNβ 
CD45.1+ C57/B6 wildtype splenocytes were depleted of CD19+ B cells and 
CD3ε+ T cells using magnetic bead enrichment, following manufacture’s protocol 
(Miltenyi, San Diego CA). Following depletion, different concentrations of OVA I 
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peptide were added to the depleted presenting cells, such that the final concentrations 
would be 1pM, 1nM, and 1 µM once plated in vitro. Naïve, CD8 enriched, CFSE labeled 
OT-1 cells were prepared as previously described, and 1x105 OT-1s were put into culture 
with 4x105 presenters along with 2ng/mL mIL-2.  Each condition was plated in triplicate, 
+/- 100 units of recombinant human IFNβ (Peprotech, Rocky Hill, NJ) for 72 hours 
before checkpoint expression was investigated using flow cytometry as previously 
described 
Direct Ex Vivo Antigen Detection Assay With Experienced T Cell Responders 
 To lower the threshold for IFNγ production, this assay was first performed with 
previously activated responding OT-1 T cells. Briefly, whole splenocytes from a OT-1 
Rag2-/- mouse were pulsed with 1 nM OVA I peptide, and 2ng/mL murine IL-2 
(Peprotech, Rocky Hill, NJ). Cells were spun down and resuspended in new media, 
containing 2ng/mL IL-2 on days 2 and 4. On Day 5, CD8+ T cells were isolated by 
magnetic bead isolation (Miltenyi, San Diego, CA), and CFSE labeled with 5µM as 
previously described. In parallel, mice were infected on a staggered timeline with 106 pfu 
Vaccinia-OVA or 107 cfu Listeria-OVA, such that, when spleens were harvested on day 
5, vaccinations had been in vivo for 72, 48, 24, and 12 hours. From these presenters, 
spleens were harvested as previously described, RBCs were lysed, and 2x105 presenting 
cells were plated with 2x104 CFSE labeled, antigen experienced OT-1s for 6 hours. 
Following the first six hour incubation, protein transport inhibitor cocktail was added, 
and an additional six hour culture was performed, before cells were stained for IFNγ 
96 
 
expression as a readout of OVA presentation. For controls, known concentrations of 
peptide were incubated with T cell depleted splenocytes as presenters. 
Cyclic Dinucleotide Stimulation 
CD8+ OT-1 T cells were enriched as previously described. 1-1.5x106 cells were 
adoptively transferred into congenically marked host mice (CD45.1+). One day alter, 
mice were vaccinated subcutaneously with either Addavax emulsion (Invivogen, San 
Diego, CA) with 10µg of Endofit whole OVA protein (Invivogen, San Diego, CA), +/- 
76µg of cyclic dinucleotides (Aduro Biotech, Berkley, CA). As a control for activation 
without PD-1 up regulation, some mice were vaccinated intraperitoneally with 107 
Listeria-OVA. On day 6 following vaccination, draining lymph nodes were harvested, 
and stained to identify adoptively transferred cells as well as expression of checkpoint 
proteins in response to the two vaccines. 
Results 
Production of IFNβ By Host Cells Is Not Responsible for CD8+T cell                  
Activation Without PD-1 Expression 
IFNβ is a type I interferon protein, and as such, is often a characteristic of 
responses to viral pathogens. However, several groups have identified IFNβ production 
as a key feature of innate immune system’s response to Listeria Monocytogenes 130. To 
test if exposure of CD8+ T cells to IFNβ was responsible for CD8+ T cell activation 
without expression of PD-1, we designed an in vitro model of CD8+ T cell activation 
where we titrated in increased amounts of OVA peptide to simulate different levels of 
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TCR stimulation in the presence or absence of IFNβ. Despite its role in generation of the 
innate immune response, and its ability to up regulate CD69 on for CD8+ T cells (Fig 6-
1a), IFNβ signaling did not decrease expression of PD-1, and in fact, may have increased 
expression of both PD-1 and LAG-3, and subsequently decreased overall divisions (Fig 
6-1b,c). Therefore, skewing of the CD8+ T cells by the presence of excess IFNβ during 
the generation of the immune response was not responsible for the activation of CD8+ T 
cells without PD-1 expression 
CD8+ T Cell Activation Without PD-1 Expression Is Not A Function of Decreased 
Peptide Presentation By Listeria-OVA Vaccination 
However, when CD8+ T cells were stimulated with a low dose of OVA peptide, in 
the absence of IFNβ we did see activation of the OT-1s without up regulation of PD-1 
(Fig 6-1b,c), suggesting to us that perhaps, these two vaccinations result in different 
amounts of OVA peptide being presented in the context of MHC I. Therefore, to test if 
Listeria vaccines present less OVA peptide than Vaccinia vaccines, we utilized a Direct 
Ex vivo Antigen Detection (DEAD) Assay, where we co-cultured experienced OT-1s 
with splenocytes from vaccinated mice at different time points. Since experienced CD8+ 
T cells are licensed and primed, they are capable of detecting extremely low levels of 
their target peptide, and responding through the production of IFNγ along with other 
cytolytic effectors molecules. As a control, we also co-cultured our experienced OT-1s 
with splenocytes pulsed with different concentrations of OVA peptide. Surprisingly, we 
found that these vaccines present OVA peptide with different kinetics. Vaccinia-OVA 
vaccination results in early peak display of MHC I:OVA complex, while Listeria-OVA 
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requires 24 hours to reach the peak of MHC:OVA expression (Fig 6-2a,b). Furthermore, 
Listeria based vaccination resulted in significantly more MHC:OVA expression, though 
both vaccines were in the range of 1-5pM effective peptide presentation when compared 
with peptide pulsed controls. Therefore, lack of PD-1 expression on CD8+ T cells primed 
against attenuated Listeria Monocytogenes was not due to decreased TCR signaling, as 
Listeria based vaccinations actually presented more peptide to experienced OT-1s. 
Activation of CD8+T Cells Without PD-1 Up Regulation Is Independent of MyD88 
Expression By Host Antigen Presenting Cells 
 MyD88 is an adaptor protein that has been found to be important in the 
identification and integration of innate immune signals within the immune system, 
including the development and maturation of dendritic cells. Indeed, MyD88 knockout 
animals have increased susceptibility to a variety of bacterial pathogens, since all Toll-
Like Receptors (except TLR3) signal through MyD88 recruitment160. To examine 
whether CD8+ T cell activation without PD-1 up regulation was a function of one of the 
MyD88 dependent toll-like receptor signaling pathways, we utilized MyD88 knockout 
host animals. After vaccination with Listeria-OVA, we examined the expression of 
checkpoint proteins on adoptively transferred OT-1s in wildtype and MyD88 knockout 
hosts. Interestingly, despite the large number of innate immune receptors that signal 
through MyD88, MyD88 knockout host animals were equally capable of generating 
CD8+ T cell activation without PD-1 up regulation (Fig 6-3a,b). However, we did see 
significant up regulation of LAG-3 on the responding CD8+ T cells. While the molecular 
mechanisms that govern the expression of individual checkpoint proteins are not 
completely understood, these data suggest that there are individual pathways in the 
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antigen presenting cells responsible for modulating the expression of individual 
checkpoint proteins on the responding CD8+ T cell population, and that checkpoint co-
expression is not completely redundant. These data further suggest that the molecular 
signaling pathway responsible for generating CD8+ T cell activation without PD-1 
expression by attenuated Listeria Monocytogenes is independent of MyD88, and 
therefore independent of all MyD88 signaling pathways, including many of the TLRs. 
Stimulation of the STING Pathway is Not Sufficient To Generate                                     
CD8+ T cell Activation Without PD-1 Up Regulation 
 Another pathway that has recently been implicated in the host sensing of Listeria 
Monocytogenes is the Stimulator of Interferon Genes (STING) pathway. STING is an 
intracellular signaling receptor that has been reported to sense the cyclic dinucleotides 
produced in large quantities by Listeria, as well as several other pathogens124. To test the 
role STING plays in the priming of CD8+ T cells to Listeria based vaccines, we attempted 
to intentionally stimulate the STING pathways during CD8+ T cell activation. Utilizing 
Addavax as the emulsion, we vaccinated mice with subcutaneous whole OVA protein 
with or without the addition of cyclic dinucleotides, the ligands for STING. In this model, 
we found that stimulating the STING pathway was not sufficient to generate a CD8+ T 
cell phenocopy of vaccination with Listeria-OVA, and that the addition of CDNs may 
have actually increased checkpoint expression rather than decrease it (Fig6-4a,b). These 
data suggest that it is not simply stimulation of the STING pathway that prevents PD-1 
up regulation, though it does not discount the requirement for STING in combination 
with other pathways. 
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STING Pathway Signaling is Not a Requirement For The Generation Of Anti-Tumor 
Immunity By Live, Attenuated Listeria Vaccination 
 We also wanted to examine the effects of STING signaling in the generation of 
anti-tumor immunity by either Vaccinia or Listeria vaccinations. To test this, we gave 
STING knockout animals B16-OVA intravenously, followed by the same vaccination 
strategy as previously described. In agreement with the CDN stimulation studies, we 
found Listeria vaccinations still had significantly decreased tumor burden (Fig 6-5a,b) as 
well as superior overall survival (Fig 6-5c),  suggesting that STING is not required for the 
generation of anti-tumor immunity to Listeria based vaccinations.  
Summary 
 The generation of a successful CD8+ T cell response is dependent on the 
recognition of the pathogen by the innate immune system, specifically by professional 
antigen presenting cells, such as dendritic cells. Following antigen recognition, dendritic 
cells mature and present antigens to CD8+ and CD4+ T cells to prime subsequent 
expansion and maturation of these cells. The pathways that are stimulated by an 
individual pathogen depend on characteristics of that pathogen, including the production 
of 5’ triphosphorylated RNA, flagellin expression, or a myriad of other pathogen 
associated molecular patterns. In the case of Listeria, many different pathways all seem 
to play some role in the maturation of the innate immune response, as well as the 
generation of a potent adaptive immune response. However, IFNβ production, MyD88 
signaling, and STING signaling were all unnecessary for the generation of a CD8+ T cell 
activation phenotype with PD-1 expression. These data support one of two hypothesis. 
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The first is that these pathways overlap, and therefore combinations of their signaling 
results in the CD8+ T cell activation phenotype we observe when using this live-
attenuated strain of Listeria. A second hypothesis is that stimulation of a specific 
pathway, not examined here, is responsible for the CD8+ T cell phenotype. One pathway 
we did not examine here was RIG-I stimulation, as the in vivo tools for examining this 
pathway are only recently becoming available. However, together these data demonstrate 
that STING and MyD88 are likely dispensable for activation of CD8+ T cells without up 
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Figure 6-1: Activation of CD8+ T Cells Without PD-1 Expression is Not Due To 
IFNβ Skewing by Host Cells 
A) Splenocytes were incubated overnight at in 100U/mL of rIFNβ before being stained 
for CD69 up regulation on CD8+ T cells. B) CFSE labeled OT-1s were cultured with 
splenocytes pulsed with different concentrations of OVA peptide +/- 100U/mL of rIFNβ 
for 3 days before being stained for PD-1 expression. C) Repeat wells were quantified for 
PD-1 expression. Data shown are representative of at least 2 independent experiments, 












































 Figure 6-2: Listeria Vaccination Produces Increased Functional Presentation of 
OVA Peptide 
Host mice were given staggered vaccinations of either Vaccinia-OVA or Listeria-OVA, 
and harvested after the indicated time in vivo. 2x105 splenocytes were co-cultured with 
2x104 CFSE labeled, previously activated, OT-I CD8+ T cells for 6 hours in the presence 
of protein transport blockade. Following co-culture, cells were directly stained for 
IFNγ production. A) Dot plots gated on CFSE+ CD8+ T cells. B) Quantification of 
replicate wells. Data shown are representative of at least 2 independent experiments, with 























Figure 6-3: Listeria Vaccine Driven CD8+ T Cell Activation Without PD-1 Up 
Regulation Is Mediated By A Pathway Independent of MyD88 
CFSE labeled OT-1s were admixed with their vaccine and then adoptively transferred 
into recipient host mice, either congenically marked CD45.1+ wildtype or MyD88 -/- mice, 
or CAG-OVA mice for a tolerizing control. On day three, spleens were harvested, and 
splenocytes stained for checkpoint protein expression. A) Cells were gated on CFSE 
expression as well as CD8 and CD45.2, before being examined as for expression of 
individual checkpoint proteins and B) quantified. Data shown are representative of at 




















Figure 6-4: Stimulation of the STING Pathway is Not Sufficient for CD8+ T Cell 
Activation Without PD-1 Up Regulation 
OT-1 T cells were magnetically enriched as previously described, and transferred into 
new hosts. One day later, host mice were challenged subcutaneously with Addavax + 
OVA protein, with or without the addition of cyclic dinucleotides. Some mice were 
challenged with Listeria-OVA as a control for activation without PD-1 up regulation. 5 
days following challenge, adoptively transferred cells were examined in the challenge 
draining lymph nodes. A) Dot plots of PD-1 and LAG-3 expression and B) Quantification 
of checkpoint protein expression. Data shown represent at least 2 independent 










Figure 6-5: The Protective Immunity Generated by Listeria Monocytogenes 
Vaccination is Independent of STING Signaling 
STING-/- host mice were injected intravenously with 1-1.5x105 B16-OVA. Three days 
later, mice were vaccinated with either PBS, 107 cfu of Listeria-OVA, or 106 pfu of 
Vaccinia-OVA via intravenous injection. Mice were then A-B) harvested on day 18 for 
measurement of tumor load or C) monitored for survival. Data shown represent at least 2 
independent experiments, with n=4 mice per group. 
















LISTERIA MONOCYTOGENES VACCINATIONS INDUCE A UNIQUE 





 Professional antigen presenting cells, such as dendritic cells, are responsible for 
the generation of potent adaptive immune responses161,162. However, it is now understood 
that the primary populations of professional antigen presenting cells are not one 
homogenous population, but instead made up of many different subsets based on function 
and location. Dendritic cells, originally identified by Paul Langerhans, represent the 
major functional population of cells capable of priming adaptive immunity through the 
activation and subsequent licensing of CD4+ and CD8+ T cells to generate a primary 
response, as well as develop a memory response for lifelong protective immunity. Recent 
work by a variety of labs has demonstrated that spleen and lymph node resident dendritic 
cells can also be broadly divided into several subgroups.  One of these groups, the CD8α+ 
dendritic cell subset, has recently been implicated in the presentation of tumor associated 
antigens to the adaptive immune system163. 
CD8α+ dendritic cells (CD8α+ DC) require the transcription factor BATF3164 as 
well as FLT-3 signaling165,166, and have been found to have highly efficient cross 
presentation potential167–169. This means they can efficiently transfer antigens found 
outside the cell onto an MHC I protein, which is normally restricted to internal antigens, 
allowing these cells to generate CD8+ T cell responses to external antigens. Furthermore, 
the cross presentation potential of this population is likely linked to its capacity to 
scavenge dead and dying cells168, and is crucially important in the generation of anti-
tumor CD8+ T cell responses. Furthermore, prior to activation, this subset of dendritic 
cells plays a role in tolerizing the immune response to dying cells170. Interestingly, 
CD8α+ DCs may require type I interferons to fully mature and promote CD8+ T cell 
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responses171, suggesting a role for the interplay of these different dendritic cell subsets. 
CD8α− DC have not been as well characterized as the CD8α+ DC subset, though this may 
be due to the possibility that there are multiple DC subsets represented within the CD8α− 
DC population. However, it has been shown that CD8α− DCs are not efficient at cross 
presentation, but may be more effective at the generation of a CD4+ T cell response. 
Since they are the gatekeepers to productive adaptive immunity, dendritic cells 
have a tightly regulated maturation program, constantly sampling their environments for 
foreign molecules, and when activated, initiating a molecular program that specializes 
them for T cell activation in response to a pathogen. Given the functional differences 
associated with different dendritic cell subsets, as well as the functional differences 
associated with other potential antigen presenting cells, set out to determine if Listeria 
and Vaccinia vaccinations utilized the same or different populations of primary antigen 
presenting cells. If different populations of professional APCs were responsible for 
priming CD8+ T cell responses to these two vaccinations, this could potentially explain 
the different expression of PD-1 on the surface of these CD8+ T cells, as well as the 
difference in anti-tumor immunity. However, if the same population of professional 
APCs were responsible for the priming of CD8+ T cell responses, then the programming 
of those APCs and the subsequent activation of the CD8+ T cells must be different due to 






Chapter Specific Materials and Methods 
Direct ex vivo Antigen Detection (DEAD) Assay With Experienced or Naïve T Cells 
Direct ex vivo antigen detection assays with antigen experienced cells were 
performed as previously described, with one key exception. For the presenting 
population, populations of professional antigen presenting cells from the spleens of host 
mice were combined and depleted of CD19+ B and CD3ε+ T cells using magnetic bead 
enrichments and sorted using the following identification markers: B cells: CD3ε-
CD19+DX5-, Granulocytic Myeloid Cells: CD3ε-CD19-DX5-CD11BhiLy6GhiLy6Cint, 
Monocytic Myeloid Cells: CD3ε-CD19-DX5-CD11BhiLy6G-Ly6Chi, CD8α- Dendritic 
Cells: CD3ε-CD19-DX5-CD11ChiCD8α-, and CD8α+ Dendritic Cells: CD3ε-CD19-DX5-
CD11ChiCD8α+. For the B cell population, a small fraction of the initial splenocyte 
population was left undepleted prior to sorting. Following FACS sorting, populations 
were recounted. Cells were plated in complete RPMI in a 96 well round bottom plate 
with 2x105 presenting cells and 2x104 CFSE labeled CD8+ OT-1 T cells for six hours. 
After the first six hour incubation, protein transport blockade cocktail was added, and an 
additional 6 hours of culture was used to restimulate the cells prior to staining for IFNγ.  
 For stimulation of naïve T cell populations, the same process as above described 
was used to isolate the sort the presenting populations. However, naïve OT-1 T cells, just 
isolated and enriched by magnetic bead selection, were CFSE labeled, and co-cultured 
with presenters at the above ratios in the presence of 2 ng/mL mIL-2 for 72 hours. After 3 
days in culture, cells were examined for CFSE dilutions, and checkpoint protein 
expression by flow cytometry. 
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 RNA Extraction, Microarray Generation, and Microarray Analysis 
 For the generation of microarray data, host mice were vaccinated 24 hours prior to 
harvest with either PBS, 1x106 pfu Vaccinia-OVA, or 1x107 Listeria-OVA via tail vein 
injection. As shown previously (Fig  4-1, 4-3. and 5-1) these vaccine doses result in 
roughly equivalent division of cognate antigen-specific T cells in vivo. Spleens were 
harvested as previously described, and B and T cells were depleted by magnetic bead 
selection, as described for the DEAD assay. CD8α+ dendritic cells were sorted with the 
same sorting strategy previously shown. Following sorting, RNA extraction was 
performed using a RNEASY Micro kit (Qiagen, San Diego, CA) following the 
manufacturer’s instructions, and including homogenization with a Qiagen cell 
shredder(Qiagen, San Diego, CA). RNA was eluted from the column, and flash frozen 
using dry ice and liquid nitrogen, before being submitted to the JHU Deep Sequencing 
and Microarray Core Facility. RNA was amplified using Nugene technology, and run on 
an Affymetrix Mouse Gene 2.0ST chip (Affymetrix, Santa Clara, CA). Hybridization 
signal was harvested using an Affymetrix Gene Chip system. Intensity data was 
converted into fold change, and P values calculated using Partek analysis software 
(Partek, Singapore). Figures and tables were generated using Spotfire analysis software 
(Tibco, Boston, MA). 
Multi-Target Co-Culture Assay 
 For the modified transwell assay experiments, antigen presenting dendritic cells 
were generated and harvested as seen previously for the DEAD assay experiments. 
Briefly, animals were vaccinated 24 hours prior to harvest (with either 1x106 Vaccinia-
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HA or 1x107 Listeria-OVA), spleens were pooled, RBCs lysed, and B and T cells were 
depleted prior to sorting CD8α+ dendritic cells as seen previously. CD8+ OT-I T cells and 
CD8+ Clone 4 T cells were magnetically isolated and CFSE labeled as seen previously. T 
cells populations were mixed such that 2x104 of both OT-I and Clone 4 T cells were 
present in each well of the 96 well plate. Presenting CD8α+ dendritic cells were added as 
described, either alone or mixed, along with 2ng/mL mIL-2 (Figure 7-8) (Peprotech, 
Rocky Hill, NJ). After 72 hours, cells were stained for markers of interest, and run on a 
LSR II instrument. 
Results 
Listeria-OVA Vaccine Associated Antigens Are Presented Exclusively By Monocytic 
Myeloid Cells and CD8α+ Dendritic Cells 
 To test the hypothesis that Listeria-OVA and Vaccinia-OVA associated antigens 
were being presented by two different populations of professional antigen presenting 
cells, we had to first determine the populations of cells capable of presenting Listeria-
OVA associated antigens within the context of MHC I. To explore the different 
populations of possible professional antigen presenting cells, we utilized a DEAD assay 
similar to the previous studies, but with FACS sorted populations of professional antigen 
presenting cells. After reviewing markers of different professional antigen presenting 
cells in the literature, we designed a FACs sorting panel to isolate and sort to >97% 
purity six different possible populations of potential professional antigen presenting cells; 
namely, B cells, monocytic myeloid cells, granulocytic myeloid cells, Ly6C- Ly6G- 
myeloid cells, CD8α- dendritic cells, and CD8α+ dendritic cells (Fig 7-1). Following 
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FACS sorting, we co-cultured these cells with previously activated OT-I T cells, and 
looked for IFNγ production as a method of determining expression of OVA in the context 
of MHC I. Surprisingly, despite the variety of populations available for infection, 
Listeria-OVA associated antigens were only presented to CD8+ T cells by the monocytic 
myeloid cells and the CD8α+ dendritic cells (Fig 7-2a,b). These data suggest that, despite 
the large number of possible antigen presenting cells, vaccinations in vivo are likely being 
targeted to a small number of professional antigen presenting cells. 
Listeria Monocytogenes Is Found In CD8α+ Dendritic Cells Early During the Immune 
Response, Followed By Later Localization In Monocytic Myeloid Cells 
 To confirm the findings from the DEAD assay, we wanted to examine whether 
Listeria could be found in one or both of the populations previously identified. To do 
this, we utilized a Listeria Monocytogenes vector which had been genetically modified to 
express green fluorescent protein (GFP), and examined the different populations of 
antigen presenting cells. As can be seen, GFP expression was only found in the 
monocytic myeloid and CD8α+ dendritic cell populations during the time assayed. 
However, the kinetics of uptake were different between the two populations, with 
Listeria-GFP being found initially in the CD8α+ dendritic cell population as early as 60 
minutes following infection (Fig 7-3). GFP signal was not detected in the monocytic 
myeloid population until 24 hours, suggesting that these two populations have different 
capabilities for either infection or phagocytic uptake of the attenuated Listeria 
Monocytogenes vector. Surprisingly, only a small fraction of either population was seen 
to be GFP positive in this assay, further suggesting that only a small subset of 
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professional antigen presenting cells were being activated by these vaccines, and that 
these cells have an extremely high functional capability for the activation of CD8+ T 
cells. 
Naïve CD8+ T Cells Are Primed by CD8α+ Dendritic Cells In Response                           
To Both Listeria and Vaccinia Based Vaccinations 
 While OVA peptide was being presented to experienced CD8+ T cells by both 
monocytic myeloid cells and CD8α+ dendritic cells, priming a naïve CD8+ T cell 
response requires multiple signals, including co-stimulation and cytokine production. 
Therefore, we wanted to test whether naïve CD8+ T cells could be primed in vitro by the 
professional antigen presenting populations previously examined. Furthermore, we 
wanted to know which professional antigen presenting population was primarily 
responsible for priming CD8+ T cell responses during Vaccinia-OVA vaccination. Using 
the same FACS sorting panel as previously described, we co-cultured these cells with 
CFSE labeled, naïve CD8+ T cells. In this system, we found that CD8α+ dendritic cells 
were the most robust stimulators of naïve CD8+ T cell responses for either Listeria or 
Vaccinia vaccination (Fig 7-4a,b). Interestingly, when co-cultured with CD8α+ dendritic 
cells from a CAG-OVA mouse, naïve CD8+ OT-I T cells were stimulated to divide by all 
the professional antigen presenting populations, showing that each of these populations 
can prime naïve OT-1s if OVA peptide is being presented in the context of MHC I. We 
also saw a small amount of naïve CD8+ T cell priming by the monocytic myeloid cells 
when vaccinated with Listeria-OVA, which is in line with the presentation of OVA by 
these cells in the previous assay. However, since the monocytic myeloid cells were far 
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less potent than the CD8α+ dendritic cells, we believe that the most biologically 
significant population of professional antigen presenting cells for both Listeria and 
Vaccinia vaccinations is the CD8α+ dendritic cell population. These data suggest that the 
differences in CD8+ T cell expression of checkpoint proteins was not due to the 
utilization of different professional antigen presenting cell populations. 
CD8α+ Dendritic Cells From Listeria Vaccinated Mice Are Sufficient                           
For CD8+ T Cell Activation Without PD-1 Up Regulation 
 While the CD8α+ dendritic cells FACS sorted from vaccinated mice were capable 
of stimulating naïve CD8+ T cells to divide, it was still possible that other innate immune 
cells or soluble factors were responsible for the CD8+ T cell activation without PD-1 up 
regulation in vivo. Therefore, we wanted to examine the capability of CD8α+ dendritic 
cells from vaccinated mice to regulate PD-1 expression on CD8+ T cells during 
activation. Naïve OT-1s co-cultured with CD8α+ dendritic cells from a CAG-OVA host 
divided in response to their antigen, as seen previously, but expressed large amounts of 
PD-1. However, despite utilizing the same professional antigen presenting cell 
population, Listeria-OVA vaccinated CD8α+ dendritic cells were sufficient to activate 
naïve OT-1s without allowing PD-1 up regulation, while co-culture with Vaccinia-OVA 
vaccinated CD8α+ dendritic cells resulted for similar expression of PD-1 as seen in the in 
vivo adoptive transfer studies (Fig 7-5). Interestingly, naïve OT-1s activated in vitro by 
CD8α+ dendritic cells from a host animal receiving Listeria-OVA vaccination may 
express even less PD-1 than was seen in the in vivo adoptive transfer studies, suggesting 
that this interaction is responsible for the in vivo phenotype. Furthermore, these data 
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show that there is a protein capable of restricting PD-1 expression that is present on or 
secreted by CD8α+ dendritic cells when they are vaccinated with this live-attenuated 
Listeria vaccine. 
Listeria and Vaccinia Vaccinations Generate Two Completely Different              
Transcriptional Programs in CD8α+ Dendritic Cells 
 In order to determine whether CD8α+ dendritic cells respond differently to 
Listeria and Vaccinia vaccinations, we examined the transcriptional profile of Listeria or 
Vaccinia vaccinated CD8α+ dendritic cells by microarray analysis. FACS sorting was 
performed as previously described, and post sort analysis showed that the CD8α+ 
dendritic cell populations that were analyzed by microarray were >97% pure (Fig 7-6a). 
Surprisingly, the differences in the transcriptional profile were clear even before the 
application of a significance filter, as the principal component analysis displayed very 
clear groupings (Fig 7-6b). From the global perspective, the transcriptional program 
being expressed in Listeria vaccinated CD8α+ dendritic cells was extremely different 
from the program activated in response to Vaccinia, or that expressed in resting CD8α+ 
dendritic cells (Fig 7-7). These data suggest that, despite both vaccines activating the 
same professional antigen presenting cell population, the response of the CD8α+ dendritic 
cell population to these two vaccines is incredibly different, and likely the cause of the 
differences in PD-1 expression, as well as the differences in the generation of anti-tumor 
immunity. 
 At the individual gene level, Listeria vaccinated CD8α+ dendritic cells expressed 
higher levels of several dendritic cell maturation markers, including CD80, CD86, and 
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CD70, though surprisingly, no difference in CD40 expression was seen (Table 7-1). 
Furthermore, transcripts for the intracellular sensors STING and RIGI were detected, as 
well as several chemokines and cytokines. We also saw increased levels of the 
transcription factor CISH, which has been correlated with dendritic cell maturation 
status172. In terms of genes down regulated, one gene in particular stood out. Rgs18 is a 
GTPase activating protein (GAP), which prevents G protein coupled signaling by 
hydrolyzing GTP to GDP quickly. Listeria vaccination resulted in significant down 
regulation of this gene when compared either to resting cells or to Vaccinia vaccination, 
suggesting that this protein may have a role in the maintenance of tolerance in the steady 
state of resting (or sub-optimally activated) dendritic cells (Table 7-2). Together, these 
transcripts identify a different, and potentially more potent, dendritic cell activation 
program than that of dendritic cells stimulated by vaccination with Vaccinia. 
CD8α+ Dendritic Cells From Listeria Vaccinated Mice Modulate PD-1 Expression 
During Naïve CD8+T Cell Activation In A Cell Contact Dependent Manner 
 Since the list of differentially expressed genes is rather large, we sought to 
determine if control of PD-1 expression on CD8+ T cells during activation is a function of 
soluble factors being secreted by Listeria vaccinated CD8α+ dendritic cells, or if direct 
contact between cognate T cells and antigen presenting DC is required. To test this, we 
took advantage of the previous experiments, where we saw that Listeria vaccination was 
capable of activating either Clone 4 or OT-I CD8+ T cells without substantial PD-1 up 
regulation, despite their differing genetic backgrounds and MHC I alleles (Figure 5-1, 5-
5). Therefore, we designed and performed a modified transwell assay, where we co-
cultured Listeria-OVA vaccinated CD8α+ dendritic cells (C57/B6) and/or Vaccinia-HA 
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vaccinated CD8α+ dendritic cells (B10.D2) in the same well as CFSE labeled OT-I and 
Clone 4 CD8+ T cells (Fig 7-8a). In this system, CD8+ T cells would only interact and 
form a cell-contact dependent immune synapse with their cognate CD8α+ dendritic cell 
population. However, both populations would be in culture together, so if there were 
soluble factors either promoting or suppressing expression of PD-1, these soluble factors 
would be able to affect both CD8+ T cell populations (Fig 7-8a). As in previous studies, 
when both CD8+ T cell populations were co-cultured with only Vaccinia-HA vaccinated 
CD8α+ dendritic cells, only the Clone 4 population divided, and expressed intermediate 
levels of PD-1. Furthermore, when both CD8+ T cell populations were co-cultured with 
Listeria-OVA vaccinated CD8α+ dendritic cells, only the OT-I population was stimulated 
to divide, and did not express PD-1 as previously demonstrated (Fig 7-8b). Surprisingly, 
when both populations of vaccinated CD8α+ dendritic cells were co-cultured with both 
populations of CD8+ T cells, both populations divided, and acted as if only their cognate 
CD8α+ dendritic cell population was present. Together, these data show that soluble 
factors are not the determining factor for PD-1 expression in this system, and that instead, 
some signaling pathway that requires cell to cell contact between the CD8α+ dendritic 
cells and the responding CD8+ T cell is determining the expression of PD-1 in response 
to these two vaccinations. 
Summary 
 Traditionally, it is understood that the generation of an adaptive immune response 
to a pathogen or vaccination requires that professional antigen presenting cells recognize 
the foreign material, mature in response to that stimulus, and subsequently prime naïve 
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CD8+ T cell responses to that pathogen. However, recent work has begun to identify 
different subpopulations of antigen presenting cells, such as the several different 
populations of dendritic cells that have been established. These studies have clearly show 
heterogeneity of response within a specific subpopulation of dendritic cells, dependent on 
the vaccine vector being recognized. In this chapter we have shown that both Listeria 
Monocytogenes and Vaccinia Virus are presented to the adaptive immune system by the 
same subset of professional antigen presenting cells, namely CD8α+ dendritic cells. This 
population is known for its potent cross presentation function, as well as its potential role 
in the presentation of tumor associated antigens, making a vaccine that activates this 
subset of cells a very attractive vector. Yet, despite being presented by the same 
population, we have found that manner in which the CD8α+ dendritic cells stimulate a 
CD8+ T cell response is different depending on the vaccine they have recognized. In 
vitro, co-culture of Vaccinia or Listeria vaccinated CD8α+ dendritic cells with naïve 
CD8+ T cells was sufficient to replicate the in vivo expression levels of PD-1. 
Furthermore, Listeria and Vaccinia vaccinations resulted in completely different 
transcriptional profiles in the CD8α+ dendritic cells, suggesting that this population of 
professional antigen presenting cells is capable of discerning between multiple types of 
pathogens, and responding appropriately. Finally, we found that CD8α+ dendritic cells do 
not modulate PD-1 expression on CD8+ T cells in our model through the use of soluble 
factors. This implies that there is a cell surface signaling pathway between CD8α+ 
dendritic cells and naïve CD8+ T cells that is capable of modulating PD-1 expression on 
the responding cells. This could be another attractive mechanism for clinical intervention, 
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Figure 7-1: Sorting Strategy for the Identification and Isolation of Various 
Professional Antigen Presenting Cell Populations  
To isolate different potential professional antigen presenting cell populations, cells were 
stained with a variety of extracellular markers and FACS sorted. Prior to sorting, 
splenocytes were depleted of CD3ε+ and CD19+ cells through the use of magnet bead 
enrichment. The different populations of antigen presenting cells were defined and named 
as follows: B cells: CD3ε-CD19+DX5-, Granulocytic Myeloid Cells: CD3ε-CD19-DX5-
CD11BhiLy6GhiLy6Cint, Monocytic Myeloid Cells: CD3ε-CD19-DX5-CD11BhiLy6G-





















































































Figure 7-2: Listeria Vaccination Associated Antigens Are Presented Exclusively on 
Monocytic Myeloid Cells and CD8α+ Dendritic Cells 
Populations of professional antigen presenting cells were sorted as previously described 
24 hours after intravenous vaccination with Listeria-OVA or PBS for control, peptide 
pulsed splenocytes. Following isolation of individual populations, presenting cells were 
co-cultured with previously activated, CFSE labeled OT-I CD8+ T cells for six hours 
before protein transport blockade was added, and cultured for additional six hours with 
protein transport blockade before being stained for IFNγ production. Peptide pulsed 
splenocytes were used as a positive control for peptide presentation. A) Dot plots 
depicting typical IFNγ responses and B) IFNγ production quantified and normalized to 
IFNγ production in response to 20 picomolar pulsed splenocytes. Data shown are 
representative of at least 2 independent experiments, with duplicate or triplicate wells 






Figure 7-3: Listeria is Detected in Different Populations of Professional Antigen 
Presenting Cells with Unique Kinetics 
Host mice were injected with Listeria-GFP and splenocytes were examined at the 
indicated time points for GFP expression by flow cytometry. Graph depicts percent of the 
labeled population that expressed GFP. Data shown are representative of at least 2 





















Figure 7-4: CD8α+ Dendritic Cells Are the Primary Professional Antigen Presenting 
Cell Responsible for Priming CD8+ T cells Responses to Listeria and Vaccinia 
Vaccines 
Populations of professional antigen presenting cells were sorted from congenically 
marked CD45.1 mice as previously described, 24 hours after intravenous vaccination 
with Listeria-OVA or Vaccinia-OVA. Unvaccinated CAG-OVA splenocytes were also 
harvested as positive controls for presentation of OVA peptide. Following isolation 
individual populations, presenting cells were co-cultured with naïve, CFSE labeled OT-I 
CD8+ T cells for 72 hours with 2ng/mL mIL-2 before being examined for division in 
response to a presenting population. A) Histogram analysis of dividing cells and B) 
quantification of replicate experiments. Data shown are representative of at least 3 


















Figure 7-5: Vaccinated CD8α+ Dendritic Cells Are Sufficient To Replicate the in 
vivo Checkpoint Expression Levels in vitro 
Populations of professional antigen presenting cells were sorted from congenically 
marked CD45.1 mice as previously described, 24 hours after intravenous vaccination 
with Listeria-OVA or Vaccinia-OVA. Unvaccinated CAG-OVA splenocytes were also 
harvested as positive controls for presentation of OVA peptide. Following isolation 
individual populations, presenting cells were co-cultured with naïve, CFSE labeled OT-I 
CD8+ T cells for 72 hours before being examined for division and checkpoint expression 
in response to a presenting population. A) Dot plots of PD-1 and LAG-3 expression and 
B) quantification of replicate wells. Data shown are representative of at least 3 
























































Figure 7-6: Sorting Strategy and Quality Control Analysis of Microarray Results 
24 hours prior to sorting, C57/B6 mice were vaccinated with Listeria-OVA, Vaccinia-
OVA, or PBS. Splenocytes were harvested and depleted of T cells and B cells before 
sorting through the use of magnetic bead isolation kits. To ensure appropriate cell 
number, mice from each group were divided into groups of 4, and processed and sorted 
together as one replicate. A) FACs sorting strategy and post sort analysis for purity. B) 




























Figure 7-7: CD8α+ Dendritic Cells Activate Significantly Different Transcriptional 
Programs in Response to Listeria or Vaccinia Vaccination 
C57/B6 mice were vaccinated with Listeria-OVA, Vaccinia-OVA, or PBS. Twenty four 
hours later, mice were pooled, CD8α+ dendritic cells were FACS sorted, and total RNA 
was extracted. Microarray analysis was performed using an Affymetrix gene 2.0 chip, 
and heat maps were generated using Spotfire analysis software. Heat map depicted is 
filtered on genes with a false discovery rate p value of less than 0.05 when comparing 
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Figure 7-8: Regulation of the Expression of PD-1 on CD8+ T Cells During Activation 
By CD8α+ Dendritic Cells Is Not Mediated By Soluble Factors 
CD45.1+ C57/B6 mice were vaccinated with Listeria-OVA while Thy1.2+ B10.D2 mice 
were vaccinated with Vaccinia-HA. 24 hours later, CD8α+ dendritic cells were isolated as 
previously described. Thy1.1+ Clone 4 and CD45.2+ OT-1 CD8+ T cells were isolated by 
magnetic bead enrichment, CFSE labeled, and mixed together at a 1:1 ratio. 4x104 total 
CD8+ T cells were co-cultured with 2x105 Listeria-OVA vaccinated C57/B6 CD8α+ 
dendritic cells, 2x105 Vaccinia-HA vaccinated C57/B6 CD8α+ dendritic cells, or a 
mixture of 2x105 of both populations, for a total of 4x105 dendritic cells in the mixed 
culture. After 72 hours, expression of PD-1 on the two populations of T cells was 
examined. A) A model depicting the potential for soluble factors to interact with both 
populations of T cells, while cell surface factors will be background restricted. B) Flow 
cytometric analysis of PD-1 expression, gated on CD8, CFSE, and the proper congenic 
markers. Data shown are representative of at least 3 independent experiments, with 
























Table 7-1: Top Genes Up Regulated in Response to Listeria Vaccination in CD8α+ 
Dendritic Cells 
Using Partek and Spotfire analysis software, transcript expression level was calculated as 
fold change vs. Vaccinia vaccinated CD8α+ dendritic cell expression levels. 






Table 7-2: Top Genes Down Regulated in Response to Listeria Vaccination in 
CD8α+ Dendritic Cells 
Using Partek and Spotfire analysis software, transcript expression level was calculated as 
fold change vs. Vaccinia vaccinated CD8α+ dendritic cell expression levels. 











CONCLUSIONS AND FUTURE DIRECTIONS  
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The generation of potent, specific, anti-cancer immunity has been an aspirational 
goal of immunologists and clinicians alike. Toward this goal, significant progress has 
been made in understanding of the requirements for the generation and maintenance of 
the immune response. DNA vaccines, cell based vaccines, and live-attenuated vaccines 
all represent different methods of generating a new immune response, while checkpoint 
blockade, epigenetic therapy, and co-stimulatory signaling pathways all represent 
potential methods to refocus and reinforce a response already in progress. In pursuit of 
this goal, we have examined the anti-cancer and immunological effects of two, unique, 
live-attenuated anti-cancer vaccine vectors; Listeria Monocytogenes and Vaccinia Virus. 
Listeria based vaccinations resulted in superior control of tumor growth in multiple 
models, including multiple cancer lines as well as subcutaneous and metastatic models of 
disease. The anti-tumor effect of both vaccinations was dependent on the generation of an 
adaptive immune response, as shown by the lack of generated protection in RAG2-/- 
animals. Furthermore, the RAG2-/- mice receiving live-attenuated Vaccinia Virus 
vaccination actually died earlier, likely from the inability to control the vaccination dose. 
This highlights some of the concerns with the use of live-attenuated vaccines, and the 
status of the patients’ immune system should be carefully considered prior to clinical use. 
Furthermore, the generation of anti-tumor immunity for our Listeria based vaccination 
was dependent on the generation of a CD8+ T cell response, unlike the anti-tumor 
immunity generated by Vaccinia.  
 Since both vaccinations did generate CD8+ T cell responses, though Listeria 
based vaccines generated a larger population, we thought there must also be functional 
differences in the CD8+ T cells being primed, and therefore set out to utilize an adoptive 
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transfer model to study the earliest phenotypes of the responding CD8+ T cells. We found 
that Listeria based vaccinations resulted in early increases in the percentage of cells 
producing single as well as multiple cytokines. CD8+ T cells responding to Listeria-OVA 
produced more IFNγ, more TNFα, and more Granzyme B, all suggesting the potential for 
increased cytolytic activity on a per cell basis. However, CD8+ T cells responding to 
Vaccinia-OVA produced more IL-2, which may represent the viral nature of this vector 
and therefore, the necessity for both a CD4+ T cell and B cell response to be generated. 
These data were some of the first data we found supporting the hypothesis that these two 
vaccines were resulting in different programming of the resultant CD8+ T cell population. 
Listeria resulted in increased expression of not all cytokines, but of certain, cytolytic 
cytokines. In terms of transcription factors, while Vaccinia vaccination did increase 
expression of the activating CD8+ T cell transcription factors, it also resulted in up 
regulation of Egr2, a protein known in the CD4+ T cell literature to be associated with 
anergy and a lack of function. This was unlike the response to Listeria vaccination, where 
there was little Egr2 expression, and increased Tbet and Eomesedermin expression. The 
role of Egr2 in CD8+ T cell biology is not fully understood, and is a potential area for 
further exploration, as Egr2 expression may decrease overall cytolytic function in CD8+ 
T cells as well.  
The most pronounced difference between the CD8+ T cell responses generated by 
these vaccines was the expression, or lack thereof, or the checkpoint proteins PD-1 and 
LAG-3. Recent publications from our lab, as well as others, have highlighted the roles of 
PD-1 and LAG-3 in the maintenance of peripheral tolerance as well as tumor tolerance. 
Furthermore, it is also known that blockade of PD-1 or LAG-3 can result in recovery of 
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function, increased cytokine production, and increased expansion not only in self-
tolerance and tumor models, but also in models of chronic and acute infection. 
Classically, it is thought that the expression of checkpoint proteins during CD8+ T cell 
activation is a requirement or side effect of the activation. However, in these studies, we 
found that PD-1 and/or LAG-3 expression is not a requirement of activation, but instead 
part of a specific program that can be prevented in the proper circumstances. Indeed, 
while the CD8+ T cells responding to Vaccinia vaccination did up regulate PD-1 and 
LAG-3, CD8+ T cells responding to Listeria vaccination did not express either of these 
checkpoints. The lack of PD-1 expression was further verified by comparison of PD-1 -/- 
OT-I CD8+ T cells to wildtype OT-I CD8+ T cells vaccinated by Listeria. Even when 
compared to genetic knockout animals, wildtype OT-I CD8+ T cells expressed negligible 
amounts of PD-1 when responding to Listeria vaccination. Decreased expression of these 
two checkpoint proteins was not simply a function of the adoptive transfer model, as both 
a different adoptive transfer model (B10.D2 background) and examination of the 
endogenously generated tetramer positive cells showed similar results to these two 
vaccinations. Surprisingly, we found that Listeria and Vaccinia vaccines showed 
equivalent anti-tumor immunity when utilized in a PD-1 knockout host, suggesting that 
PD-1 expression is the molecular distinction that creates the functional difference for 
these two vaccines. Clinically, these data support the combination of checkpoint blockade 
therapy with vaccine strategies, as expression of PD-1 during the vaccination clearly 
affects the efficacy of the generated immune response. Furthermore, since many vaccines 
are known to cause PD-1 and LAG-3 expression during their priming phase, it is 
important to block these checkpoint proteins to achieve maximum efficacy. However, 
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these data are the first to demonstrate that some vaccines, such as this attenuated form of 
Listeria Monocytogenes,may activate a program in CD8α+ dendritic cells that can 
suppress up regulation of these checkpoint proteins, or at least minimize their expression. 
This is not to say that no checkpoint proteins are expressed, and further research will be 
necessary to examine other potential regulatory signaling molecules that may be 
compensating for PD-1 and LAG-3 in this system.  
Finally, the role of the antigen presenting cells utilized by a vaccine strategy 
needs to be further explored when developing a vaccination platform. In these data, we 
have shown that both our attenuated Listeria Monocytogenes and Vaccinia Virus utilize 
one single population of dendritic cells, despite the large number of subpopulations 
capable of presenting antigen to CD8+ T cells. CD8α+ dendritic cells are a subpopulation 
of the conventional dendritic cell lineage, and have been shown to be particularly 
powerful generators of CD8+ T cell responses. While previous research has shown that 
the presence of CD8α+ dendritic cells is required for entrance of Listeria into the splenic 
architecture, it has never been clearly demonstrated that these dendritic cells are uniquely 
and specifically responsible for the generation of a CD8+ T cell response to Listeria 
Monocytogenes. In these studies, we have shown that CD8α+ dendritic cells are the main 
population of dendritic cells responsible for priming in vivo responses to Listeria 
Monocytogenes based vaccinations, and that these cells alone are sufficient to drive CD8+ 
T cell activation without the up regulation of PD-1 expression. The understanding of the 
targeted dendritic cell subset is important for the design of combination experiments. For 
example, early data describing the effects of GM-CSF from B16-GVAX in preclinical 
models has suggested that this vaccine expands out CD8α- dendritic cells. When 
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combining a cell based vaccine with Listeria, it therefore may be more beneficial to 
utilize a therapy that expands CD8α+ dendritic cells, such as FVAX where the secreted 
soluble factor is the CD8α+ dendritic cell expanding factor Flt-3.  
However, despite the utilization of the same subpopulation of dendritic cells, the 
immune responses generated by Listeria Monocytogenes and Vaccinia Virus are clearly 
different, both in the phenotypes of the CD8+ T cells generated, as well as the general 
anti-tumor immunity. Therefore, we wanted to examine whether the differences in these 
vaccines would be reflected as early in the immune response as the antigen presenting 
cells. Surprisingly, after only twenty four hours, the transcriptional profiles of the CD8α+ 
dendritic cells responding to our two vaccinations were strikingly different. Listeria 
Monocytogenes vaccination resulted in the significant up regulation of transcripts known 
to be related to dendritic cell maturation, such as CISH, CD80, CD86, CD70, and the 
components of RIG-I signaling. Furthermore, Listeria vaccination also resulting in the 
down regulation of several signaling proteins, including RGS18, which is a GTPase 
activating protein, turning off G protein coupled signaling. Though the role of RGS18 in 
dendritic cells is relatively unknown, the down regulation of this transcript correlated 
with the up regulation of several known G protein coupled signaling pathways, 
suggesting a potential cascade effect that is involved in programming the dendritic cell to 
respond to certain stimuli, such as Listeria Monocytogenes. Nevertheless, the control of 
PD-1 expression on the CD8+ T cells responding to either Listeria or Vaccinia does not 
seem to be dependent on soluble factors. This is different than what has been seen by 
other groups, where IL-10 or TGFβ have been found to be important regulators of PD-1 
signaling. However, while those soluble factors have been found to increase PD-1 
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expression, no soluble factors to date have been shown to prevent up regulation of PD-1. 
The up regulation of this PD-1 modulating signaling pathway is independent of either 
MyD88 or STING signaling, suggesting that it is relatively specific, and not a feature of 
general dendritic cell maturation in response to pathogens. Furthermore, this pathway is 
only stimulated by Listeria that is incapable of leaving the cell it originally infects. 
Therefore, we propose a model whereby Listeria vaccination enters CD8α+ dendritic 
cells, escapes the endosome, and is stranded within the cytoplasm of these cells. From 
there, the Listeria stimulates a host innate sensing pathway that is independent of MyD88 
or STING, and results ultimately in the up regulation of a protein or proteins that are 
responsible for programming the responding CD8+ T cells to activate and expand without 
the up regulation of PD-1. Listeria also stimulates a MyD88 dependent pathway that is 
responsible for managing the level of LAG-3 expression on the responding CD8+ T cells. 
Together, these data show that different innate pathways are responsible for the 
expression of different checkpoint proteins on the resultant, adaptive immune cells. These 
data also question the requirement for checkpoint protein expression during CD8+ T cell 
activation, and demonstrates instead that checkpoints are individually regulated, and that 
their expression is not completely overlapping. Instead, the expression of each checkpoint 
may be individually mandated by the programming dendritic cell, and certain 
combinations may suggest certain signaling pathways involved or excluded during those 
cells activation or reactivation.  
In the future, studies identifying the specific pathways and sensors responsible for 
the regulation of checkpoint proteins on CD8+ T cells during activation will be of the 
utmost importance. Viral vectors could be potentially modified to generate a stronger 
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CD8+ CTL response by intentionally signaling via pathways generally reserved for 
bacterial pathogens, such as Listeria Monocytogenes. Furthermore, the protein, or 
proteins involved in the modulation of PD-1 expression on CD8+ T cells needs to be 
identified and tested. Inclusion of this stimulatory protein in cancer therapies as well as 
during vaccine regimens has the potential to further expand the effectiveness of 
immunological clinical interventions. Knowledge of these pathways will allow for 
potential clinical interventions, by which the generation of an immune response could be 
tailored towards the specific type of immunity that is necessary, not only for cancer 
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